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ABSTRACT OF THE DISSERTATION
Regulation of alpha] -adrenoceptor-mediated contractions
of the uterine artery by PKC
by
Hongying Zhang
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda University School of Medicine, May 2007
Dr. Lubo Zhang, Chairperson

Pregnancy is associated with a significant decrease in uterine vascular tone and a
striking increase in uterine blood flow, which ensures normal fetal development. Multiple
mechanisms are involved in the adaptation of uterine artery contractility during pregnancy.
Both protein kinase C (PKC) and activation of ai-adrenoceptors play important roles in
the regulation of uterine artery contractility. In addition, PKC mediates the pregnancyassociated decrease in myogenic tone of the uterine artery, and interacts with ajadrenoceptors leading to modulation of ai-adrenoceptor-mediated contractions of
vascular smooth muscle. Yet, whether or to what extent PKC regulates ai-adrenoceptormediated contractions of the uterine artery and their adaptation to pregnancy remains
unclear. The central hypothesis of the proposed studies is that PKC activation
•
differentially regulates ai-adrenoceptor-mediated Ca2"b mobilization
and sensitization in

pregnant and nonpregnant uterine arteries. To test this hypothesis, we proposed a series
of experiments in the uterine arteries obtained from nonpregnant and near-term (~140
Days) pregnant sheep.

x

We found that PKC activation has opposite effects on ai-adrenoceptor-mediated
contractions in pregnant and nonpregnant uterine arteries. In pregnant uterine arteries
PKC activation inhibited ai-adrenoceptor-mediated contractions through suppressing
Ca2+ -dependent thick-filament regulatory pathway with decreased Ca2+ mobilization and
phosphorylation of 20-kDa regulatory light chain of myosin (LC20). This inhibitory effect
of PKC activation was reversed by PKC isozyme-selective inhibitory peptides for
PKCpi, (311 and s. In contrast, in nonpregnant uterine arteries PKC activation potentiated
a 1-adrenoceptor-mediated contractions through enhancing thin- filament regulatory
pathway with increased Ca" sensitivity and phosphorylation of extracellular signalregulated kinase44/42 (ERK44/42) and Caldesmon-Ser

70Q

without changing the

phosphorylation level of LC20. This potentiating effect of PKC activation was reversed by
PKC isozyme-selective inhibitory peptides for conventional PKCs, PKCpi, pil and c.
The differential regulation of PKC isozyme expression, basal activity and reactivity, with
the up-regulation of PKCp and PKC^, and the down-regulation of PKCa and PKCs, is
7_l_

# #

#

7_j_

likely to play an important role in the regulation of Ca" mobilization and Ca sensitivity
in a 1-adrenoceptor-mediated contractions and their adaptation to pregnancy.

xi

CHAPTER ONE
GENERAL INTRODUCTION
Introduction
Physiological Changes of Uterine Artery during Pregnancy
During pregnancy there are dramatically physiological changes in the maternal
cardiovascular system to ensure normal fetal development. The striking alterations in
arterial size and function during pregnancy are very unique to the uterine artery. As
pregnancy progresses, the uterine blood flow increases around 20 folds in human and
ovine (Palmer et al., 1992; Rosenfeld, 1977). In late pregnancy, the uterine circulation
carries about one fifth of the maternal cardiac output, with around 80% of the uterine
blood flow going to the placenta. The uterine circulation during pregnancy functions as a
low-resistance shunt to accommodate the large increase of uteroplacental blood flow,
required for normal fetal development. The decreased uterine artery resistance is
accomplished by growth and remodeling of vessels, increased endothelial nitric oxide
(NO) release, decreased myogenic response, and a reversible sympathetic denervation of
the uterine artery.
The marked changes of the uterine artery structure during pregnancy accommodate
the substantial increases in uterine blood flow. Pregnancy-related increase in diameter of
uterine artery was found in human (Annibale et al., 1990; Palmer et al., 1992), pig
(Guenther et al., 1988) and sheep (Fuller et al., 1975). The uterine artery in late-term
pregnant sheep significantly enlarged to 5.0 mm or greater in diameter, compared with
2.8 mm in nonpregnant sheep (Fuller et al., 1975). In addition to dilation of vessel, the
increase in arterial diameter during pregnancy accompanys with a 2.5-fold increase in
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smooth muscle mass per unit length of vessel, in spite of no change in arterial wall
thickness (Griendling et ah, 1985). Growth in cell length also contributes to the increase
in uterine arterial diameter seen in pregnancy, although the number of cells per unit area
and the diameter of the cells are unchanged (Annibale et ah, 1990). Meanwhile, the
biochemical changes in the uterine artery during pregnancy have also been detected.
Pregnancy significantly increased protein contents of the uterine arteries from sheep but
did not affect the fractional cellular composition of the muscularis, compared with
nonpregnant sheep (Annibale et ah, 1990). The increase in contractile protein contents
might contribute to the increases in stress of uterine arterial smooth muscle associated
with pregnancy.
In addition to the growth of new vessels and remodeling of existing vessels during
early pregnancy, the increasing nutrient demands of the fetus over the latter part of
gestation are met predominantly through decreasing uterine arterial vascular smooth
muscle tone, resulting in progressive increases in arterial diameter and uterine blood flow
(Rosenfeld, 1984). Despite the extensive studies, the mechanisms of pregnancy-induced
decrease in uterine arterial vascular tone are not fully understood. Previous studies have
been focused on the adaptation of endothelium to pregnancy and indicated that increased
endothelail nitric oxide synthase (eNOS) expression (protein and/or mRNA) and
increased NO synthesis/release play important roles in vasodilation of the uterine artery
during pregnancy (Kanashiro et ah, 2000; Magness et ah, 1996 and 1997; Li et ah, 1996;
Sladek et ah, 1997; Weiner et al., 1991; Xiao et al., 2001a and 2001b), The adaptation of
contractile mechanisms of uterine arterial smooth muscle to pregnancy is less clear.
Studies in Dr. Lubo Zhang’s laboratory have recently demonstrated in ovine uterine
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arteries that protein kinase C (PKC) plays an important role in the regulation of uterine
artery contractility, and the pregnancy-associated decrease in myogenic tone of the
uterine artery is primarily regulated through the PKC signaling pathway (Xiao and
Zhang, 2002; Xiao et ah, 2004 and 2006). In addition to its regulatory effect of myogenic
tone (Davis and Hill, 1999; Xiao et ah, 2006), PKC interacts with ai-adrenoceptors and
modulates ai-adrenoceptor-mediated contractions of vascular smooth muscle (Ford,
1995; Minneman, 1988; Nishizuka, 1992). Activation of ai-adrenoceptors plays a key
role in the regulation of uterine artery smooth muscle contractions (Cox et ah, 2004;
Ford, 1995; Magness and Rosenfeld, 1986; Stjemquist and Owman., 1990; Zhang et ah,
1995). Yet, whether or to what extent PKC regulates ai-adrenoceptor-mediated
contractions of the uterine artery and their adaptation to pregnancy remains unclear.

The Role of PKC in the Regulation of Smooth Muscle Contraction
PKC is a key enzyme involved in the regulation of diverse cellular processes such
as growth, differentiation, metabolism, secretion, and smooth muscle contraction
(Horowitz et ah, 1996b; Nishizuka, 1992; Walsh et ah, 1996). There are at least 11 PKC
isozymes (PKCs), divided into three major groups: 1) classical (conventional) PKCs: a,
9+

(31, (311, and y, which are activated by both diacylglycerol (DAG) and Ca ; 2) novel
PKCs: 5, 8, p, and 0, which are activated by DAG but not Ca ; 3) atypical PKCs: <^, i,
and Z, which are activated by neither DAG nor Ca . The molecular structures of PKC
isozymes are shown in Fig. 1. Phosphatidylserine (PS), DAG and phorbol esters bind to
their cysteine-rich Cl domains to activate classical and novel PKCs. C2 domain in
classical PKCs is Ca binding site that does not exist in novelor atypical PKCs. All three

3

groups of PKCs contain a pseudo-substrate or autoinhibitory domain that binds to the
substrate-binding site in the catalytic domain preventing their activation in the absence of
cofactors or activators. Phosphorylation of PKCs by themselves and PKC kinase(s) are
required for their full activity. Phosphorylation also regulates PKC subcellular
distribution and down-regulation. The a, |3I, (311, 5, 8, and

isozymes of PKCs have been

detected in vascular smooth muscle (Walsh et ah, 1996). PKCs play an important role in
regulation of smooth muscle contraction. It has been demonstrated that PKC activation
induces slow sustained contractions in many types of vascular smooth muscle (Jiang MJ,
1989; Newton AC, 1995; Singer HA, 1990) and involves in regulation of myogenic tone
(Davis and Hill, 1999; Xiao et ah, 2006). In addition, activation of PKC by phorbol
esters, synthetic analogs of DAG, has been shown to couple to a i-adrenoceptor and
regulate ai-adrenoceptor-mediated contractions in vascular smooth muscle. Both PKCmediated inhibition and potentiation of ai-adrenoceptor-mediated contractions have been
reported. Thus, activation of PKC by phorbol esters inhibited norepinephrine-induced
contractions in rat aorta, cat and sheep cerebral arteries (Bazan et ah, 1993; Cotecchia et
ah, 1985; Danthuluri and Deth, 1984; Leeb-Lundberg et ah, 1985; Longo et ah, 2000;
McMillan et ah, 1986; Salaices et ah, 1990). On the other hand, activation of PKC
potentiated ai-adrenoceptor-mediated contractions in rabbit aorta, rat mesenteric arteries,
femoral arteries, corpora cavernosa, and vas deferens (Amobi et ah, 1999; Henrion et ah,
1992; Husain et ah, 2004; Martinez et ah, 2001; Matsumura et ah, 2001). The effect of
potentiation was abolished with depleting PKC after prolonged treatment with
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conventional PKC (a, pi, pll, y)
V1
N— C1a C1b

V2

C2

V3

C
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novel PKC (6, £, n, B)
N
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C
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N
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Fig. 1. PKC kinase family members and their structure. The
conventional groups have four conserved regions (C1-C4) and five
varialbel regions (V1-V5). Cl (Cla and Clb): DAG and phorbolester binding sites. C2: Ca2+ binding site. C3: ATP binding site. C4:
PKC substrate binding sites.
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C

phorbol esters (Henrion et aL, 1992). The controversial effects of PKC on aiadrenoceptor-mediated contractions in different arteries from different species may be
due in part to the diversity of PKC isozymes, which have different enzymatic properties,
substrates, functions, and different sub-cellular distributions in different blood vessels and
species (Horowitz et ah, 1996b; Kanashiro and Khalil, 1998 & 2001, Khalil et ah, 1992;
Liou and Morgan, 1994; Nishizuka Y, 1992).

Alphai-adrenoceptor-mediated Contraction of Vascular Smooth Muscle
Activation of ai-adrenoceptors plays a key role in the regulation of uterine artery
smooth muscle contractions (Cox et al., 2004; Ford, 1995; Magness and Rosenfeld, 1986;
Stjemquist and Owman., 1990; Zhang et al., 1995). During pregnancy, uterine artery
increases acute contractile response to nonsynaptic ai-adrenergic stimulation (Annibale
et al., 1989 & 1990; D’Angelo and Osol, 1993 & 1994; Osol and Cipolla, 1993), in spite
of the vascular tone is decreased. This paradoxical event is at least partly due to the
transient and reversible sympathetic denervation of uterine artery during pregnancy
(Klukovits et al., 2002; Naves et al., 1998). As shown in Fig. 2, activation of aiadrenoceptors leads to hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2) to
inositol 1, 4, 5- trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to IP3 receptors
and stimulates Ca2+ release from intracellular calcium stores, resulting in phosphorylation
of 20-kDa regulatory light chain of myosin (LC20) and contractions. LC20 phosphorylation
is regulated through thick-filament regulatory pathway by myosin light chain kinase
(MLCK) and myosin light chain phophotase (MLCP) (Wier and Morgan, 2003). MLCK
activation by increased intracellular free Ca2+ concentration ([Ca2+]j) and Ca2+/calmodulin

6

binding leads to an increase in phosphorylated LC20 (P-LC20) and contraction. Inhibition
of MLCP activity increases Ca sensitivity of contraction through decreasing
dephosphorylation of P-LC20. On the other hand, DAG activates PKC that has been
suggested to play a key role in a 1-adrenoceptor-mediated contraction by regulating Ca2+
sensitivity (Buus et ah, 1998; Gailly et al., 1997; Kitazawa et ah, 2000; Martinez et al.,
2000; Nishimura et al., 1990; Sato et al., 2001).
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Fig. 2. Signal transduction pathway ofaj-adrenoceptor-mediated contraction in vascular
smooth muscle cell.
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Contractile Mechanisms in Vascular Smooth Muscle
Smooth muscle contraction is regulated through changes in intracellular Ca2+
mobilization and the Ca2+sensitivity of the contractile apparatus. An increase in [Ca2+]j
leads to activation of MLCK and subsequent phosphorylation of LC20 and contraction
(Horowitz et ah, 1996; Pfitzer, 2001), a mechanism tenned Ca" -dependent thick-filament
regulation. The Ca2+sensitivity, defined by force production per unit changes in [Ca2+]i, is
another important mechanism to regulate vascular contractility. Regulation of the
Ca2+sensitivity of myofilaments is through both Ca2+-independent thick-filament regulatory
pathway that involves inactivation of MLCP resulting in an increase in LC20
phosphorylation independent of changes in [Ca ]j (Somlyo and Somlyo, 2003), and the
thin-filament regulatory pathway that leads to an increase in contraction independent of
changes in LC20 phosphorylation (Morgan and Gangopadhyay, 2001).
9-4-

PKC has a dual role in regulation of ai-adrenoceptor-mediated Ca mobilization
and Ca sensitization. It is well known that a 1-adrenoceptor induces Ca mobilization in
smooth muscle mainly through production of IP3 leading to Ca" release from
intracellular Ca2+stores (Garcia-Sainz et al., 2000; Suzuki et ah, 1990). PKC has been
suggested to desensitize a 1-adrenoceptor resulting in decreases in a 1-adrenoceptormediated PIP2 hydrolysis, IP3 production and Ca mobilization (Garcia-Sainz et al.,
2000; Leeb-lundberg et al., 1985 and 1987; Lynch et al., 1985; Schimmel et al., 1986;
9-4-

• •

Suzuki et al., 1990; Vazquez-Prado et al., 1996). PKC regulates Ca sensitivity of
myofilaments through Ca -independent thick-filament regulatory pathway. CPI-17 is a
smooth muscle-specific protein and phosphorylated CPI-17 at Thr-38 (p-CPI-17/Thr58)
becomes an inhibitor of the catalytic activity of MLCP (Wier and Morgan, 2003). PKC
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can phosphorylate CPI-17 and enhance its inhibitory potency 1000-fold (Kitazawa et ah,
2000). In the meantime, ratio of expression of CPI-17 to MLCP correlates with PKCinduced Ca2+ sensitization (Wier and Morgan, 2003; Woodsome et ah, 2001). In addition
to the thick filament regulation, PKC also regulates Ca sensitivity through the thin
filament mechanisms. It has been suggested that PKC mediates contraction in the uterine
artery predominantly through the thin filament regulatory pathway (Xiao et ah, 2003).

Thin Filament Regulation of Smooth Muscle Contraction and the Major
Thin Filament-associated Proteins
Thin filaments are defined as those filaments 6-8 nm in diameter and composed of
filamentous actin. The thin filament signal transduction pathway is regulated through
both Ca2+ and LC20 phosphorylation independent mechanisms. The existence of thin
filament regulation is supported by the following evidences: 1) LC20 phosphorylation
levels (myosin or thick filament regulation) do not parallel with tension levels (Dillon PF,
1981); 2) crossbridge cycling rates vary without detectable changes in LC20
phosphorylation (Butler et al., 1986; Haeberle, et al., 1985); 3) contraction may occur
without changes in LC20 phosphorylation (Menice et al., 1997). Thin filament regulatory
proteins include caldesmon and calponin.

Caldesmon
Caldesmon (CaD) is a thin filament-associated, actin, tropomyosin, myosin and
calmodulin (CaM) binding protein and plays an important role in thin-filament
regulation. The molecular structure of CaD is shown in Fig. 3. Carboxy terminal
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DOMAIN STRUCTURE OF GIZZARD CALDESMON
IK29C

53
25
IAYQRNDDDEEEAARERRRRAROERLRQK-C
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1
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27

651

667

MDDFERRRELPRQKREEMRLEAERLSY-C

666 718

COOH

CaM
A E

Myosin
CaM

Actin
Actin
ERK:SER702(759)
PAK:SER 657, 687

Fig. 3. Domain structure of caldesmon, modified from Lee et al. (J Biol Chem 275:3213-20, 2000)
Numbering is according to the chicken gizzard sequence, except that the analogous mammalian
Extracellular regulated kinase (ERK) phosphorylation site (759) is given after the ERK gizzard
phophorylation site and the peptide IK29C is from the human sequence. CaM, calmodulin. Tm,
tropomyosin; PAK, p21-activated kinase.
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domains are responsible for actin binding and inhibition of myosin ATPase activity. The
N-terminal half of the molecule has been shown to bind myosin. CaD acts as a cross
linker of actin and myosin. CaD plays an important inhibitory role in the regulation of
smooth muscle tone through inhibiting myosin ATPase activity (Katsuyama et al., 1992;
Morgan and Gangopadhyay, 2001; Wier and Morgan, 2003; Word et al., 1993). CaD’s
•

o|

endogenous inhibitory effect on myosin ATPase is regulated by the binding of Ca -CaM
and/or the phosphorylation of its C-terminal actin binding domains (Morgan and
Gangopadhyay, 2001). It is known that CaD is phosphorylated in vitro by a number of
protein kinases including CaM kinase II, casein kinase II, protein kinase A, cdc2 kinase,
extracellular signal-regulated kinase (ERK), and PKC. Phenylephrine has been suggested
to induce phosphorylation of CaD through activating PKC and/or mitogen-activatedprotein kinases (MAPKs) (Dessy et al., 1998; Horowitz et al., 1996a). PKC can directly
or indirectly phosphorylate CaD and induces sustain contractions (Horowitz et al., 1996a;
Morgan and Gangopadhyay, 2001; Throckmorton et al., 1998; Xiao and Zhang, 2005). In
9-1-

addition, CaD has been suggested to be a good substrate of Ca -independent isozyme
PKCs but not PKC^ (Horowitz et al., 1996a). Additionally, phosphorylation of CaD by
PKC is exclusively within the C-terminal 35-KDa domain (Tanaka et al., 1990) at
different sites at Serl27, Ser587, Ser600, Ser657, Ser686, Ser726, Ser759 and Ser789
(Hedges et al., 2000; Ikebe and Homick, 1991; Vorotnikov et al., 1994; Yamboliev et al.,
2000), which may be due to agonist-, species-, and tissue-specific effects (Morgan and
Gangopadhyay, 2001). Nonetheless, the resent studies suggested that, in pregnant uterine
artery, phorbol 12, 13-dibutyrate (PDBu)-induced phosphorylation of CaD at ERK
specific site of Ser789 may inhibit PKC-mediated phosphorylation of the other sites and
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stabilize CaD inhibitory effect on actin-activated myosin ATPase (Xiao et ah, 2004). This
finding was supported by other reports that phosphorylation of CaD by MAPK had no
2+

effects on Ca sensitivity in rabbit smooth muscle and cannot induce contractions of
smooth muscle (Nixon et ah, 1995). Previous study from Dr. Zhang’s laboratory has
shown that ERK inhibitor PD-098059 blocked PKC activator PDBu induced
phosphorylation of CaD-Ser

700

in uterine artery (Xiao et ah, 2004), which indicated that

ERK is a downstream molecule from PKC in the pathway of regulation of Ca2+sensitivity
(Fig.4.). On the other hand, CaD content was suggested to be different in different types
of smooth muscle (Haeberle et ah, 1992) and significantly increased in myometrium of
pregnant women, which facilitated adaptation of uterus to pregnancy (Word et ah, 1993).
However, whether or to what extent ERK and CaD involve in PKC-regulated aiadrenoceptor function and contractions in pregnant and nonpregnant uterine arteries are
not defined.
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Calponin
Calponin (CaP) is another family of actin regulatory protein that interacts with
actin and inhibits myosin ATPase activity (Morgan and Gangopadhyay, 2001; Gimona et
ah, 1992). CaP activity is regulated by phosphorylation by PKC or CaMKII, both of
which reverse CaP’s inhibitory activity (Winder and Walsh, 1990). In addition to binding
to actin, CaP can also bind to calmodulin (Wills et al., 1993), myosin (Shirinsky et al.,
1992), desmin (Mabuchi et al., 1997) and phospholipids (Bogatcheva and Gusev, 1995).
It has been suggested that CaP play an important role in the regulation of agonist-induced
contraction of vascular smooth muscle (Walsh, 200). The role of CaP in smooth muscle
contractility is controversial. CaP has been suggested to directly inhibit myosin ATPase
activity to regulate contractility of smooth muscle (Winder and Walsh, 1990). On the
other hand, it has been proposed that CaP, as a signaling molecule, facilitates PKC and
ERK-dependent signaling, leading to smooth muscle contraction (Je et al., 2001; Menice
et al, 1997; Morgan and Gangopadhyay, 2001; Leinweber et al., 1999 & 2000). Morgan
and Gangopadhyay (2001) proposed that CaP serves as an adaptor protein that binds with
PKC and ERK upon stimulation of ai-adrenoceptor agonist or phorbol ester, and
cotranslocates with these enzymes to the cell membrane as a complex. At the membrane,
ERK is phosphorylated and then releases from the membrane to its target protein CaD.
The subsequent phosphorylation of CaD by ERK reverses the inhibitory effect of CaD on
myosin ATPase to generate contraction of smooth muscle.
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Hormonal Regulation of the Uterine Artery Contractility
Steroid hormone appears responsible for the changes in uterine arterial tone and
contractility throughout pregnancy. During pregnancy, vascular tone is strikingly
decreased as estrogen concentrations rise. It has been suggested that estrogens directly
modulate proliferation and migration of endothelial and vascular smooth muscle cells
(Ford SP, 1995; Morales et al., 1995). In addition, estrogens as vasodilators have both
genomic and non-genomic actions on vasodilation. The effects of estrogens are mediated
by initially interaction with estrogen receptors that are expressed in vascular endothelium
and smooth muscle cell (Karas et al., 1994; Suzuki et al., 2003; Venkov et al., 1996).
Chronic estrogen exposures alter vascular tone mainly through genomic mechanism by
which estrogen receptors regulate transcription of target gene expression. It has been
reported that estrogens increase gene expressions of endothelial nitric oxide synthase
(eNOS) (Caulin-Graser et al., 1997; Joyce et al., 2002), phospholipase A2 (Rupnow et al.,
2002), prostacyclin synthetase (Rupnow HL, 2002) and cyclooxygenase-1 (Jun, et al.,
Rupnow et al., 2002) but decrease expressions of prostaglandin H synthase (Stewart et
al., 1999) and endothelin-1 (Akishita et al., 1988) in endothelium. For many years of in
vivo study of the ovarian and pregnant effect on uterine artery vasodilation, Dr. Magness
and his colleagues have demonstrated that estrogen increase eNOS gene expression and
NO synthesis in uterine artery from sheep (Joyce et al., 2002; Magness et al., 1996, 1997
& 2001; Rupnow et al., 2001; Vagononike et al., 1998). A rapid and direct effect of
estrogens was also postulated, which may be the result of non-genomic responses. The
regulation of nitric oxide (NO) synthesis and/or release is a major target of estrogen in
endothelium to produce vasodilation. Besides chronicly increasing its synthesis,
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estrogens directly enhance eNOS activity (Caulin-Graser et al., 1997) and inhibit NO
degradation, because estrogens are potent antioxidants (Amal et al., 1996). Meanwhile,
estrogens acutely modulate Ca homeostasis in vascular smooth muscle cells resulting in
a rapid decrease in vascular tone via endothelia-independent mechanisms. Estrogens have
been shown to directly interact with and open smooth muscle cell calcium-activated
potassium channels, thus relaxing the cell (Valverde et al., 1999). Furthermore, estrogens
have been reported to regulate potential-sensitive calcium channels (PSC). Peroxidase
9-1-

converts estrogens to catechol estrogens, which directly inhibit Ca uptake throught
PSC, resulting in a decreased PKC-maintained tone of uterine artery (Ford, 1995; Ford, et
al.). During pregnancy, extremely high concentrations of estrogens and peroxidase are
detected in uterine lymphatic fluid that are in close contact with the uterine arterial
vasculature and thus may serve to transport catechol estrogens (Ford et al., 1993). It has
been indicated that the decreasing PKC activity of uterine artery during pregnancy is
associated with catechol estrogen-induced inhibition of calcium uptake through PSC
(Farley and Ford, 1992). Progesterone, in contrast to estrogen, inhibits proliferation and
migration of endothlia and vascular smooth muscle cells (Lee et al., 1997; Schnaper et
al., 2000). Meanwhile, progesterone augments the responsiveness of vascular smooth
muscle to norepinephrine related to enhancing PKC activity. During the estrous cycle of
ewes, the higher the estrogen: progesterone ratio in systemic blood, the greater is the
quantity of blood flowing through the uterine vascular bed. However, after the initial
increase in blood flow to the uterus during early pregnancy, changes in uterine blood
flow appear to be unrelated to changes in the estrogen: progesterone ratio in fetal and
maternal fluids. Since the estrogen: progesterone ratio controls uterine blood flow
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through changes in the function of periaterial adrenergic nerves, the disassociation
between the estrogen: progesterone ratio and uterine blood flow may relate to a
progressive sympathetic denervation observed in the uterus during pregnancy.

Aim of this project
The aim of the present project was to examine the main hypothesis that PKC
activation differentially regulates ai-adrenoceptor-mediated Ca mobilization and
sensitization in pregnant and nonpregnant uterine arteries. To test this hypothesis, we
proposed a series of experiments in uterine arteries from nonpregnant and near-term (~140
days) pregnant sheep. Our specific aims were: 1) to test the hypothesis that PKC
differentially regulates a i-adrenoceptor-mediated contractions of nonpregnant and
pregnant uterine arteries; 2) to test the hypothesis that PKC activation differentially
regulates a i-adrenoceptor-mediated Ca" mobilization and sensitization in pregnant and
nonpregnant uterine arteries through differentially regulations of the thick and thin
filament pathways; 3) to test the hypothesis that differential regulation of PKC isozyme
activities contributes to the different effect of PDBu on aj-adrenoceptor-mediated
contractions between the pregnant and nonpregnant uterine arteries.

Significance
The proposed studies are of importance from both basic science and clinical
2~h

perspectives. From the basic science point of view, the proposed studies of both Ca dependent and Ca -independent pathways are especially powerful means of evaluating
regulatory mechanisms governing uterine artery contractility, and thereby enhance our
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basic understanding of uterine vasculature adaptation to pregnancy. They will provide
exciting novel information from several standpoints. They will be the first to examine
PKC isozyme expression and their functions in the uterine artery, and examine the effect
of pregnancy. They will be the first to offer assessment of the dynamic interactions of
PKC and a i-adrenoceptor-induced signal transduction pathways in the uterine artery, and
to test the novel hypothesis that PKC differentially regulates ai-adrenoceptor function
and contractions in nonpregnant and pregnant uterine arteries. They will be the first
concerted effort to understand the mechanisms underlying the dual role of PKC in the
regulation of contractions in the uterine artery. Not only are these studies important to
understand basic mechanisms underlying adaptation of uterine artery contractile
machinery to pregnancy, but they will also offer novel information in understanding
signaling mechanisms for vascular contraction in general.
The proposed studies are relevant to the mechanisms involved in adjusting
uteroplacental circulation to pregnancy. Given the importance of uterine blood flow in fetal
development and maternal health, failure to make these adjustments is likely to contribute to
many fetal abnormalities, including intrauterine growth restriction, as well as maternal
cardiovascular disorders. The proposed studies will help provide a mechanistic basis for this
functional adaptation, and thereby improve our understanding of problems associated with
the maladaptation and abnormal pregnancy and permit us to address them in a more
meaningful way.

19

CHAPTER TWO

REGULATION OF ai-ADRENOCEPTOR-MEDIATED CONTRACTION OF THE
UTERINE ARTERY BY PKC: EFFECT OF PREGNANCY

Hongying Zhang, DaLiao Xiao, Lawrence D. Longo and Lubo Zhang

This chapter appeared in publication in the American Journal of Physiology (Heart Circ
Physiol) 291(5): H2282-9, 2006.
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Abstract

Protein kinase C (PKC) plays an important role in the regulation of uterine artery
contractility and its adaptation to pregnancy. The present study tested the hypothesis that
PKC differentially regulates ai-adrenoceptor-mediated contractions of nonpregnant and
pregnant uterine arteries. Phenylephrine-induced contractions of uterine arteries isolated
from nonpregnant (NPUA) and near-term pregnant (PUA) sheep were determined in the
absence or presence of the PKC activator, phorbol 12, 13-dibutyrate (PDBu). In NPUA,
PDBu produced a concentration-dependent potentiation of phenylephrine-induced
contractions and shifted the dose-response curve to the left. In contrast, in PUA PDBu
significantly inhibited phenylephrine-induced contractions and decreased their maximum
response. Simultaneous measurement of contractions and intracellular free Ca2+
concentrations ([Ca ]i) in the same tissues revealed that PDBu inhibited phenylephrineinduced [Ca ]j and contractions in PUA. In NPUA, PDBu increased phenylephrineinduced contractions without changing [Ca ]j. Western blot analysis showed six PKC
isozymes, a, pi, Pn, 8, s and

in uterine arteries, among which pi, pn and

isozymes

were significantly increased in PUA. In contrast, PKCa was decreased in PUA. In
addition, analysis of sub-cellular distribution revealed a significant decrease in the
particulate/cytosolic ratio of PKCs in PUA, as compared with NPUA. The results suggest
that pregnancy induces a reversal of PKC regulatory role on a i-adrenoceptor-mediated
contractions from a potentiation in NPUA to an inhibition in PUA. The differential
expression of PKC isozymes and their sub-cellular distribution in uterine arteries appears
to play an important role in the regulation of Ca mobilization and Ca sensitivity in aiadrenoceptor-mediated contractions and their adaptation to pregnancy.
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Introduction

Pregnancy is associated with a significant decrease in uterine vascular tone and a
striking increase in uterine blood flow, which ensures normal fetal development. Multiple
mechanisms are involved in the adaptation of uterine artery contractility during pregnancy
(3, 12, 38,48, 50). We have recently demonstrated in ovine uterine arteries that protein
kinase C (PKC) plays an important role in the regulation of uterine artery contractility,
and the pregnancy-associated decrease in myogenic tone of the uterine artery is primarily
regulated through the PKC signaling pathway (45, 48, 50). In addition to its regulatory
effect of myogenic tone (10, 45), PKC interacts with ai-adrenoceptors and modulates ajadrenoceptor-mediated contractions of vascular smooth muscle (12, 35, 37). Activation
of ai-adrenoceptors plays a key role in the regulation of uterine artery smooth muscle
contractions (7, 12, 28, 41, 51). Yet, whether or to what extent PKC regulates aiadrenoceptor-mediated contractions of the uterine artery and their adaptation to
pregnancy remains unclear.
Activation of ai-adrenoceptors leads to hydrolysis of phosphatidylinositol 4,5bisphosphate (PIP2) to inositol 1, 4, 5- trisphosphate (IP3) and diacylglycerol (DAG). IP3
binds to IP3 receptors and stimulates Ca release from intracellular calcium stores. On
the other hand, DAG activates PKC that has been suggested to play a key role in a\adrenoceptor-mediated Ca sensitization (4, 13, 24, 31, 36, 40). In addition to its
coupling to a 1-adrenoceptors, activation of PKC by phorbol esters, synthetic analogs of
DAG, has been shown to regulate a 1-adrenoceptor-mediated contractions in vascular
smooth muscle. Both PKC-mediated inhibition and potentiation of a 1-adrenoceptor-
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mediated contractions have been reported. Thus, activation of PKC by phorbol esters
inhibited norepinephrine-induced contractions in rat aorta, cat and sheep cerebral arteries
(2, 6, 9, 25, 27, 34, 39, 53). On the other hand, activation of PKC potentiated aiadrenoceptor-mediated contractions in rabbit aorta, rat mesenteric arteries, femoral
arteries, corpora cavernosa, and vas deferens (1, 14, 18, 32, 33). The effect of
potentiation was abolished by depleting PKC after prolonged treatment with phorbol
esters (14). The controversial effects of PKC on ai-adrenoceptor-mediated contractions in
different arteries from different species may be due in part to the diversity of PKC
isozymes, which have different enzymatic properties, substrates, functions, and different
sub-cellular distributions in different blood vessels and species (15, 21, 22, 23, 26, 37).
The present study tested the hypothesis that activation of PKC differentially
regulates a i-adrenoceptor-mediated contractions of uterine arteries from nonpregnant and
pregnant sheep. Concentration-response curves of phenylephrine-induced contractions of
the uterine arteries were conducted in the absence or presence of the PKC activator
phorbol 12, 13-dibutyrate (PDBu). To evaluate the role of Ca2+ in the PKC-mediated
effects, phenylephrine-induced contractions and free intracellular Ca2+ concentrations
([Ca" ]i) were measured simultaneously in the same tissues of uterine arteries. In
addition, the differential expression of PKC isozymes and their sub-cellular distributions
in nonpregnant and pregnant uterine arteries were determined.
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Methods

Tissue preparation. Nonpregnant and near-term pregnant (~140 day gestation)
ewes were anesthetized with thiamylal (10 mg/kg), administered via the external left
jugular vein. The ewes were then intubated, and anesthesia was maintained with 1.52.0% halothane in O2 throughout the surgery. An incision was made in the abdomen to
expose the uterus. The uterine arteries were isolated and removed without stretching and
were placed in a modified Krebs’ solution (pH 7.4) of the following composition (in
mM): 115.2 NaCl, 4.7 KC1, 1.80 CaCl2, 1.16MgS04, I.I8KH2PO4, 22.14 NaHC03, 0.03
EDTA, and 7.88 dextrose. The Krebs’ solution was oxygenated with a mixture of
95%02-5% CO2. After the tissues were removed, animals were killed with T-61
euthanasia solution (Hoechst-Roussel; Somerville, NJ). All procedures and protocols
used in the present study were approved by the Animal Research Committee of Toma
Linda University and followed the guidelines in the National Institutes of Health Guide
for the Care and Use ofLaboratoiy Animals.
Contraction studies. The third (in nonpregnant ewes) and fourth (in pregnant
ewes) branches of the main uterine arteries with similar external diameter were dissected
and cut into 2 mm ring segments. Isometric tension was measured in the Krebs’ solution
in a tissue bath at 37 °C as described previously (50). Briefly, each ring was equilibrated
for 60 min and then gradually stretched to the optimal resting tension as determined by
the tension developed in response to 120 mM KC1 added at each stretch level. Tissues
were then stimulated with cumulative additions of phenylephrine in approximate one-half
log increments to generate a concentration-response curve, and contractile tensions were
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recorded with an online computer. After washing away phenylephrine, tissues were
relaxed to the baseline and were recovered at the resting tension for 30 min. The second
concentration-response curves of phenylephrine-induced contractions were then repeated
in the absence or presence of PDBu (10, 30, and 100 nM for nonpregnant uterine arteries,
and 0.1, 0.3, and 1 pM for pregnant uterine arteries, for 10 min). The different
concentration ranges of PDBu were chosen in nonpregnant and pregnant uterine arteries,
based on our previous findings that PDBu was 10-time more potent in contracting
nonpregnant than pregnant uterine arteries (pDii 6.64 ± 0.07 vs. 5.62 ±0.17) (48). To
determine the effects of PDBu on phenylephrine-induced contractions, concentrations of
PDBu less than EC50 values in nonpregnant and pregnant uterine arteries, respectively,
were utilized in the present study. The concentrations of phenylephrine were chosen to
produce full concentration-response curves in both nonpregnant and pregnant uterine
arteries.
Simultaneous measurement of[Ca2+]i and tension. Smooth muscle [Ca2+]i were
measured simultaneously with muscle contractions in the same tissues as described
previously (52). Briefly, the arterial ring was attached to an isometric force transducer in
2+

a 5-ml tissue bath, mounted on a CAF-110 intracellular Ca analyzer (Jasco; Tokyo,
Japan). The tissue was equilibrated in HEPES buffer (in mM, 115.2 NaCl, 4.7 KC1, 1.80
CaCl2, 1.16 MgS04, 1.18 KH2PO4, 10.0 HEPES, 0.03 EDTA, and 7.88 dextrose, PH7.4)
under a resting tension of 0.5 g for 40 min, followed by stimulation with 120 mM KC1
once and recovery to the resting tension for 30 min. The tissue was then loaded with 5
pM fura-2 AM for 3 h in the presence of 0.02% cremophor EL and 0.25% DMSO at 25
°C. After loading, the tissue was washed with HEPES buffer at 37 °C for 45 min to allow
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for hydrolysis of fura-2 ester groups by endogenous esterase. The tissue was then
stimulated with 120 mM KC1 twice. After recovery for 30 min, the tissue was stimulated
Phenylephrine 1

PDBu
Wash+Recovery Phenylephrine 3
Phenylephrine 2

Wash+Recovery

with phenylephrine (3 pM for both nonpregnant and pregnant uterine arteries to produce
sub-maximal contractions, and 30-200 nM for nonpregnant uterine arteries to produce
less than 50% of KC1 maximum) in the absence or presence of 0.1 pM PDBu. The
experimental protocol was shown in the following diagram:
Agonist-induced changes in contractile force and fura-2 fluorescence were measured
simultaneously at 37 °C in the same tissue. The tissue was illuminated alternatively (125
Hz) at excitation wavelengths of 340 and 380 nm, respectively, by means of two
monochromators in the light path of a 75-W xenon lamp. Fluorescence emission from the
tissue was measured at 510 nm by a photomultiplier tube. The fluorescence intensity at
each excitation wavelength (F340 and F380, respectively) and the ratio of these two
fluorescence values (Rmo/sso) were recorded with a time constant of 250 ms and stored
with the force signal on a computer.
Measurement of PKC isozymes. To determine the protein expression of PKC
isozymes in uterine arteries, tissues (third or fourth branches of nonpregnant and pregnant
uterine arteries, respectively) were homogenized in the lysis buffer containing Tris-HCl
20 mM, sucrose 250 mM, EDTA 5 mM, EGTA 5 mM, 0.2% Triton X-100, (3mercaptoethanol 10 mM, benzamidine 1 mM, phenylmethylsulfonyl fluoride (PMSF) 1
mM, leupetin 50 pM, dithiothreitol 1 mM and aprotinin 2 pg/ml, pH7.5. Homogenates
were centrifuged at 6,000 g for 5 min at 4 °C and the supernatants were collected. Protein
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was quantified with a protein assay kit (Bio-Rad). Western blotting was performed as
described below.
Measurement of PKC isozyme distribution and relative activity. To determine
the distribution of PKC isozymes in cytosolic and particulate fractions of uterine arterial
smooth muscle, tissues (third or fourth branches of nonpregnant and pregnant uterine
arteries, respectively) were homogenized in ice-cold homogenization buffer A containing
Tris-HCl 20 mM, sucrose 250 mM, EDTA 5 mM, EGTA 5 mM, p-mercaptoethanol 10
mM, benzamidine 1 mM, phenylmethylsulfonyl fluoride (PMSF) 1 mM, leupetin 50 pM,
dithiothreitol 1 mM and aprotinin 2 pg/ml, pH 7.5. The homogenates were centrifuged at
100,000 g for 20 min at 4 °C, and the supernatants were collected and used as the
cytosolic fraction (S). The pellets were re-suspended in homogenization buffer A
containing 1% triton X-100 by stirring for overnight at 4 °C, diluted with the buffer A to
a final concentration of 0.2% triton X-100, and then centrifuged at 100,000 g for 20 min
at 4 °C. The supernatants were collected and referred to as the particulate fraction (P).
Protein concentrations were determined with a protein assay kit (Bio-Rad).
Immunoreactive bands for PKC isozymes in cytosolic and particulate fractions were
determined by Western blotting using specific PKC isozyme antibodies as described
below. The ratio of P/S was used to determine the relative activity of PKC isozymes.
Western immunoblotting analysis. Protein-matched samples obtained from the
tissues or cytosolic and particulate fractions were subjected to electrophoresis on 7.5%
sodium dodecylsulfate-polyacrylamide gel, and then transferred electrophoretically to
nitrocellulose membranes. The membranes were incubated at room temperature for 1 h in
Tris-buffered saline solution (TBS) containing 5% dried milk and 0.5% Tween 20,
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followed by incubation with primary anti-PKC isozyme antibodies overnight at 4 °C and
secondary antibody for 1 h at room temperature. Polyclonal antibodies to PKCa, pi, pn, 8,
e,

y were used. Bands were detected with enhanced chemiluminsecence (ECL),

visualized on Hyperfilm, and analyzed with the Kodak ID image analysis software. To
determine the total PKC levels, the same amount of protein (5 pg) from each sample was
loaded to the gel. To normalize the loading variation of each sample, the corresponding
actin level presented in each sample was determined by using monoclonal anti-actin as
primary antibody. To determine ratio of P/S, equal volume (10 pi) of cytosolic and
particulate fractions, respectively, from each sample was loaded to the gel.
Materials. Phenylephrine, PDBu, and anti-actin antibody were obtained from
Sigma (St. Louis, MO). Anti-PKC isozyme antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Fura-2 AM was from Molecular Probes (Eugene, OR).
All electrophoretic and immunoblot reagents were from Bio-Rad. General laboratory
reagents were of analytical grade or better and were purchased from Sigma and Fisher
Scientific. All drugs were prepared freshly each day and kept on ice throughout the
experiment.
Data analysis. Data were analyzed by computer-assisted nonlinear regression to
fit the data using GraphPad Prism (GraphPad software; San Diego, CA). Results were
expressed as means ± SEM. Differences were evaluated for statistical significance (P <
0.05) by one-way ANOVA and Student’s Mest.
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Results

Effect of PDBu on phenylephrine-induced contractions. Fig. 1 shows that
phenylephrine produced concentration-dependent contractions of uterine arteries from
both nonpregnant and pregnant ewes. In nonpregnant uterine arteries, PDBu (10, 30, 100
nM) induced concentration-dependent contractions, and produced a concentrationdependent potentiation of phenylephrine-induced contractions. In the presence of 100 nM
PDBu, the concentration-response curve of phenylephrine-induced contractions was
markedly shifted to the left with a significant increase in the pD2 value from 6.27 ±0.10
to 8.86 ± 0.28 (P < 0.001), representing an over 300-fold increase in the potency of
phenylephrine-induced contractions in nonpregnant uterine arteries. The maximal
responses of phenylephrine-induced contractions were not affected with PDBu (Fig. 1 &
Fig. 2). In pregnant uterine arteries, PDBu failed to induce contractions up to 1 pM,
which produced a comparable contraction (1.30 ± 0.34 g) as that induced by 100 nM
PDBu in nonpregnant uterine arteries (1.38 ± 0.74 g). As shown in Fig. 1, in contrast to
its effect in nonpregnant uterine arteries, PDBu produced a concentration-dependent
inhibition of phenylephrine-induced contractions in pregnant uterine arteries. Whereas
the pD2 values were not affected, the maximal responses of phenylephrine-induced
contractions were significantly decreased by 27%, 37%, and 68%, in the presence of 0.1
pM, 0.3 pM, and 1 pM PDBu, respectively (Fig. 1 & Fig. 2). In both nonpregnant and
pregnant uterine arteries, KCl-induced contractions were not affected with PDBu (data
not shown).
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Effect of PDBu on phenylephrine-induced changes of intracellular free Ca 2+
concentrations ([Ca ]j). Fig. 3 shows the effects of PDBu on phenylephrine-induced
increases in [Ca ]j and contractile tensions, measured simultaneously in the same tissues,
in both nonpregnant and pregnant uterine arteries. In pregnant uterine arteries, the submaximal concentration (3 pM) of phenylephrine induced significant increases in [Ca ]j
and contractile tension. PDBu (100 nM) produced a minimal contraction in the absence
of changes in [Ca ]j. In the presence of PDBu, phenylephrine-induced increases in
[Ca ]j and contractions were significantly inhibited (Fig. 3, the top panel). In
nonpregnant uterine arteries, 100 nM PDBu did not affect contractions and [Ca2+]i
induced by the sub-maximal concentration (3 pM) of phenylephrine (Fig. 3, the middle
panel). However, PDBu significantly increased contractions produced by lower
concentrations (30-200 nM) of phenylephrine, in the absence of significant changes in
phenylephrine-mediated [Ca ]i (Fig. 3, the bottom panel). After washing away PDBu
from the tissues, phenylephrine produced similar levels of increases in tension and [Ca ]i
as those before the PDBu treatment in both nonpregnant and pregnant uterine arteries
(Fig. 3), eliminating the potential time factor that could affect the responses of uterine
arteries to phenylephrine during the experiment procedure.
Expression ofPKC isozymes in uterine arteries. Fig. 4 shows the expression of
at least 6 PKC isozymes, a, pi, pn, 5, s, and ^ in ovine uterine arteries. PKCy was not
detected in either nonpregnant or pregnant uterine arteries. As compared with
nonpregnant uterine arteries, pregnant vessels showed significantly increased expression
levels of PKCpi, PKCPn, and PKC<^, but significantly decreased levels of PKCa (Fig. 4).
There were no significant differences in the expression levels of PKC5 and PKCs
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between nonpregnant and pregnant uterine arteries (Fig. 4). The distribution of PKC
isozymes in cytosolic and particulate fractions in the uterine arteries is shown in Fig. 5.
As compared with nonpregnant uterine arteries, the ratio of particulate/cytosolic
distribution for PKC isozymes in pregnant uterine arteries was significantly decreased for
PKCs, but not significantly different for PKCot, Pi, Pn, 8, and £ (Fig. 5).
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Discussion

The present study offers the following new findings: 1) activation of PKC
potentiated ai-adrenoceptor-induced contractions in nonpregnant uterine arteries, but
inhibited the contractions in pregnant uterine arteries; 2) PKC activation blocked aiadrenoceptor-mediated increases of [Ca ]j in pregnant uterine arteries, but had no
significant effect on the Ca2+ mobilization in nonpregnant uterine arteries; 3) PKC
isozyme expression and sub-cellular distribution were differentially regulated in
nonpregnant and pregnant uterine arteries, with significantly increased expression levels
of PKC (3 and PKC<^, but decreased PKCa and the basal activity of PKCe in pregnant, as
compared with nonpregnant, uterine arteries.
It has been suggested that PKC plays an important role in regulating vascular
myogenic response (10). Our recent studies have demonstrated that myogenic tone of the
uterine artery is reduced during pregnancy, which is primarily regulated through the PKC
signal pathway (45). In addition to its role in the regulation of myogenic tone, the present
study demonstrated that activation of PKC interacted with a i-adrenoceptors and
modulated a i-adrenoceptor-mediated contractions of the uterine artery. To maintain the
similar vessel diameters for nonpregnant and pregnant uterine arteries in the study, the
third and fourth branches of the main uterine arteries from nonpregnant and pregnant
sheep, respectively, were used in the present study. These vessels have been extensively
studied in our previous studies (46, 48, 49, 50), and for a comparative purpose they were
used in the present study. Similarly, the third and fourth generation uterine arteries from
nonpregnant and pregnant sheep were utilized in determining the role of Ca and Ca2+
9-4-
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channels in regulating basal and angiotensin II-induced prostacyclin production in the
uterine artery (29). Although few studies examined the potential cellular and sub-cellular
differences between branch generations of small uterine arteries, numerous studies
examined structural and signal proteins in pooled all branches of the uterine artery and
showed differences between nonpregnant and pregnant uterine arteries, including the
studies of PKC (11, 30). In the present study, we have shown that the smaller branches
(beyond the 4th generation) of pregnant and nonpregnant uterine arteries utilized in the
studies of simultaneous measurement of [Ca ]j and contractions demonstrate the same
characteristics of tissue response to PDBu and phenylephrine stimulations observed in the
3rd and 4th branches, i.e. PDBu-mediated potentiation of phenylephrine-induced
contraction in nonpregnant uterine arteries, but inhibition of that in pregnant uterine
arteries. These findings suggested that the characteristics of PKC-mediated effects were
not altered between branches of small uterine arteries. The finding that PKC differentially
regulated ai-adrenoceptor-mediated contractions in nonpregnant and pregnant uterine
arteries is intriguing, and suggests another important mechanism through which PKC
regulates the adaptation of uterine artery contractility to pregnancy. Previous studies have
demonstrated that PKC can either inhibit or potentiate ai-adrenoceptor-mediated
contractions in different arteries from different species (1, 2, 6, 9, 14, 18, 25, 27, 32, 33,
34, 39). However, to our knowledge, it has not been previously demonstrated that
activation of PKC can inhibit and potentiate ai-adrenoceptor-mediated contractions in the
same artery of the same species at different physiological states, i.e. nonpregnant and
pregnant. Thus, the present finding of a potentiation of ai-adrenoceptor-mediated
contractions in nonpregnant uterine arteries, but an inhibition in pregnant uterine arteries

33

provides a physiological importance of PKC in regulating the adaptation of aiadrenoceptor-mediated contractions of the uterine artery during pregnancy. The finding
that activation of PKC had no effect on KCl-induced contractions suggests that the effect
of PKC is selective to ai-adrenoceptor-mediated signal pathways in the uterine artery.
Similar findings were obtained in cat cerebral arteries, in which phorbol esters
potentiated phenylephrine-, but not KCl-induced contractions (39).
In the present study, activation of PKC significantly enhanced the sensitivity of
ai-adrenoceptor-mediated contractions by increasing the pDi value in nonpregnant
uterine arteries. Yet the maximal response was not affected. In contrast, in pregnant
vessels, PKC significantly decreased the maximal ai-adrenoceptor-mediated contractions
without affecting the sensitivity. These findings suggest that PKC modulates smooth
muscle contractile apparatus at different steps of signal transduction pathways responding
to ai-adrenoceptor stimulation in nonpregnant and pregnant uterine arteries. In vascular
smooth muscle cells, activation of ai-adrenoceptors leads to an increase in free
intracellular Ca2+ concentrations from intracellular Ca2+ stores via IP3 stimulation,
resulting in myosin light chain phosphorylation and contractions (35). In the present
study, we found that activation of PKC abolished a 1-adrenoceptor-induced increase in
[Ca2+]i in pregnant uterine arteries, but had no significant effect on [Ca2+]j in nonpregnant
uterine arteries. The inhibition of [Ca" ]j was accompanied by decreased contractions,
measured simultaneously in the same tissues. This suggests a predominant mechanism of
decreased Ca2+ mobilization in the PKC-mediated attenuation of a 1-adrenoceptormediated contractions in pregnant uterine arteries. Consistent with the present finding,
previous studies in ovine cerebral arteries demonstrated that PDBu inhibited

34

o I

norepinephrine-induced increases in intracellular Ca concentrations and contractions
(27). Whereas the mechanisms of PKC-mediated inhibition of Ca2+ mobilization in
pregnant uterine arteries are not clear at present, it has been demonstrated that activation
of PKC decreases agonist binding affinity of ai-adrenoceptors, increases phosphorylation
of ai-adrenoceptors, destabilizes ai-adrenoceptor mRNA, down-regulates aiadrenoceptors, and promotes uncoupling of ai-adrenoceptors from inositol phospholipid
metabolism (2, 5, 6, 19, 25, 27, 34).
In contrast to pregnant uterine arteries, the finding that PDBu had no effect on a\adrenoceptor-mediated Ca mobilization but potentiated the contractions in nonpregnant
vessels is intriguing, and provides strong evidence of increased Ca2+ sensitivity in the
PKC-mediated potentiation of ai-adrenoceptor-induced contractions in nonpregnant
uterine arteries. In the present studies of simultaneous measurement of [Ca2+]j and
contractions, the finding that PDBu had no effect on phenylephrine-induced contractions
at a high concentration (3 pM) but potentiated it at low concentrations (Fig. 3, the middle
and bottom panels) was consistent with the studies of concentration-dependent
contractions that showed the PKC-mediated potentiation occurring in the lower range
concentrations of phenylephrine (Fig. 1). These results validated that loading of tissues
with fura-2 did not alter characteristics of tissue response to PDBu and phenylephrine
stimulation, albeit the tissue size and hence the contractions were much smaller in the
studies of simultaneous measurement of [Ca ]j and contractions. Consistent with the
present findings, PKC has been implicated in the regulation of myofilament Ca2+
sensitivity in vascular smooth muscle (10, 15, 43). We have demonstrated that PKC
94-

modulates Ca sensitivity in the uterine artery predominantly through the thin-filament
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regulatory pathway, i.e. independent of changes in phosphorylation of myosin light chain
(50). Furthermore, the thin-filament pathway is an important component in ajadrenoceptor-mediated contractions, particularly in nonpregnant uterine arteries (47, 50).
Taken together, we speculate that activation of PKC in nonpregnant uterine arteries
produces a permissive and priming effect on the thin-filament pathway, resulting in
enhanced ai-adrenoceptor-induced contractions.
The apparent opposite effects of PKC on ai-adrenoceptor-mediated contractions
in nonpregnant and pregnant uterine arteries may be due in part to the differential
expression of PKC isozymes that show different enzymatic properties, substrates, and
functions (15, 23, 26). The a, p, 8, s, and C, isozymes of PKC have been detected in
vascular smooth muscle (44). Although not all of these isozymes appear to be in all vascular
smooth muscle tissues, the present study demonstrated their presence in ovine uterine
arteries. The finding of significantly increased expression levels of PKCp and PKC^ in
pregnant, as compared with nonpregnant, uterine arteries suggests a potential mechanism
for these isozymes in inhibiting a i-adrenoceptor-mediated Ca" mobilization and
contractions in the pregnant vessels. PKCp is a conventional PKC isozyme that is
•

2“b

activated by diacylglycerol and phorbol esters in the presence of Ca" (15). Previous
studies have shown that overexpression of PKCp inhibits agonist-induced Ca2+
mobilization, and inhibition of PKCp results in a dramatic increase in agonist-mediated
Ca2+ mobilization (17, 20, 42). In contrast to PKCp, inhibition of PKC^ by a specific
inhibitory peptide did not alter agonist-induced Ca" mobilization (17). In addition, PKC^
is an atypical PKC isozyme that is not activated by Ca" , DAG, or phorbol esters (15).
These results suggest that the increased PKCp in the pregnant uterine arteries is likely to
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play an important role in the PKC-mediated inhibition of a i-adrenoceptor-mediated Ca2+
mobilization and contractions in the pregnant vessels. Although PKC^ may be less likely
•

•

• •

•

*7-1-

• •

•

to be involved in the PDBu-mediated inhibition of intracellular Ca mobilization, the
increased PKC^ in the pregnant uterine arteries may be important in proliferation and
remodeling of the uterine artery during pregnancy, as it translocates from perinuclear
localization into the nucleus upon activation, and functions in control of gene expression
(8, 23, 44). In contrast to increased PKCp and PKC£, the expression levels of PKCa and
the levels PKCs in the particulate fraction were significantly decreased in the pregnant
uterine arteries. Both PKCa and PKCc have been implicated in contractions of vascular
smooth muscle through increasing Ca sensitivity (16, 43, 44). Taken together, these
findings suggest that the adaptation of the uterine artery to pregnancy is associated with the
up-regulation of the PKC isozyme(s) that inhibit intracellular Ca mobilization, and the
94-

down-regulation of the PKC isozymes that increase Ca sensitivity.
In summary, we have shown the opposite effects of PKC on ai-adrenoceptorinduced contractions in nonpregnant and pregnant uterine arteries. Activation of PKC
enhances ai-adrenoceptor-induced contractions in nonpregnant uterine arteries by
9 i

increasing Ca" sensitivity, but inhibits the contractions in pregnant uterine arteries by
decreasing intracellular Ca mobilization. The differential regulation of PKC isozyme
expression, with the up-regulation of PKCp and PKC^, and the down-regulation of PKCa
94-

and PKCc, is likely to play an important role in the adaptation of uterine artery Ca

homeostasis from pro-Ca" sensitivity in the nonpregnant vessels to inhibition of Ca2+
mobilization in the pregnant vessels. From the physiological perspective, the uterine
circulation during pregnancy functions as a low-resistance shunt to accommodate the
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large increase of uteroplacental blood flow, required for normal fetal development. In
addition to growth and remodeling of vessels, the decreased uterine artery resistance is
accomplished by increased endothelial nitric oxide release, decreased myogenic response,
and a reversible sympathetic denervation of the uterine artery. Although the decreased
sympathetic innervation may sensitize postsynaptic a i-adrenoceptor signal pathways, the
present finding of the increased inhibitory effect of PKC on a i-adrenoceptor-mediated
contractions in the pregnant uterine artery reveals another important mechanism in
maintaining the low uterine vascular tone in pregnancy. The potential effect of steroid
hormones in the regulation of differential expression of PKC isozymes in the uterine
artery during pregnancy presents an intriguing area for the future investigation.
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Figure 2. Effect of PDBu on the pD2 value and the maximal response (Tmax) of
phenylephrine-induced contractions in nonpregnant and pregnant uterine arteries.
Data are means ± SEM of tissues from 4 animals. * P < 0.05, control vs. PDBu treatment.
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Figure 3. Effect of PDBu on phenylephrine-induced intracellular free Ca2+
concentrations ([Ca2+]j) and contractions in nonpregnant and pregnant uterine
arteries. Changes of tension (ATension) and [Ca ]j (AR040/380) induced by PDBu and
phenylephrine before (PEi) and after (PE2) PDBu treatment were measured
simultaneously in the same tissues in the experimental protocol as described in the
Methods. PE3 depicts the recovery of phenylephrine-induced [Ca2+]iand contractions
after washing away PDBu from the tissues. Top Panel: Pregnant uterine arteries were
treated with 3 pM phenylephrine and 0.1 pM PDBu (n = 3). Middle Panel: Nonpregnant
uterine arteries were treated with 3 pM phenylephrine and 0.1 pM PDBu (n = 4). Bottom
Panel: Nonpregnant uterine arteries were treated with 30-200 nM phenylephrine and 0.1
pM PDBu (n = 6). Data are means ± SEM. * P < 0.05, PEi vs. PE2.
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Figure 4. PKC isozymes in nonpregnant and pregnant uterine arteries. PKC
isozymes were detected by Western immunoblotting and expressed as percentage of the
standard of each isozymes, blotted in the same membrane. Data are means ± SEM of
tissues from 4 animals. * P < 0.05, pregnant vs. nonpregnant.
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Figure 5. Subcellular distribution of PKC isozymes in nonpregnant and pregnant
uterine arteries. Cytosolic (S) and particulate (P) fractions were prepared from the
uterine arteries as described in the Methods. PKC isozymes were detected by Western
immunoblotting and expressed as the ratio of particulate/cytosolic fractions. Data are
means ± SEM of tissues from 4 animals. * P < 0.05, pregnant vs. nonpregnant.
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CHAPTER THREE

REGULATION OF ai-ADRENOCEPTOR-MEDIATED CONTRACTION OF THE
UTERINE ARTERY BY PKC: ROLE OF THE THICK AND THIN FILAMENT
REGULATORY PATHWAYS

Hongying Zhang and Lubo Zhang

This chapter was submitted for publication to Journal of Pharmacology and Experimental
Therapeutics.

55

Abstract

Previously we demonstrated that activation of protein kinase C (PKC) enhanced
a i-adrenoceptor-induced contractions in nonpregnant uterine arteries (NPUA) by
increasing the Ca sensitivity, but inhibited the contractions in pregnant uterine arteries
(PUA) by decreasing intracellular Ca2+ mobilization. The present study tested the
hypothesis that PKC activation differentially regulated the thick- and thin-filament
regulatory pathways in a i-adrenoceptor-induced contractions of NPUA and PUA in
sheep. Simultaneous measurements of contractions and phosphorylation levels of 20-kDa
regulatory myosin light chain (LC20) in the same tissue revealed that the PKC activator
phorbol 12, 13-dibutyrate (PDBu) inhibited phenylephrine-induced phosphorylation of
LC20 and contractions in PUA. In NPUA, PDBu significantly potentiated phenylephrineinduced contractions without significantly changing phosphorylation levels of LC20.
Further studies in NPUA demonstrated that PDBu-mediated potentiation of phenylephrineinduced contractions was associated with a significant increase in phosphorylation levels
of ERK42/44 and caldesmon-Ser

, measured simultaneously with the tension in the same

tissue. In addition, the ERK42/44 inhibitor PD098059 and the actin polymerization
inhibitor cytochalasin B produced a concentration-dependent inhibition of PDBumediated potentiation of phenylephrine-induced contractions in NPUA. The results
suggest that activation of PKC inhibit a 1-adrenoceptor-mediated contractions in PUA
through down-regulation of the thick filament pathway and decreased myosin light chain
phosphorylation, but enhance the contractions in NPUA through its effect on the thin
filament regulatory pathway and activation of ERK/caldesmon and actin polymerization.
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Introduction

Smooth muscle contraction is regulated through changes in intracellular Ca2+
2+

mobilization and the Ca sensitivity of the contractile apparatus. An increase in intracellular
free Ca concentration ([Ca ]j) leads to activation of myosin light chain kinase and
subsequent phosphorylation of 20-kDa regulatory light chain of myosin (LC20) and
contraction (Horowitz et ah, 1996; Pfitzer, 2001), a mechanism termed Ca2+-dependent
thick-filament regulation. The Ca" sensitivity, defined by force production per unit changes
in [Ca ]i, is another important mechanism to regulate vascular contractility. Regulation of
the Ca sensitivity of myofilaments is through both Ca -independent thick-filament
regulatory pathway that involves inactivation of myosin light chain phosphatase resulting in
an increase in LC20 phosphorylation independent of changes in [Ca ]j (Somlyo and Somlyo,
2003), and the thin-filament regulatory pathway that leads to an increase in contraction
independent of changes in LC20 phosphorylation (Morgan and Gangopadhyay, 2001).
Recently, we demonstrated that activation of protein kinase C (PKC) enhanced otiadrenoceptor-induced contractions in nonpregnant uterine arteries by increasing the Ca^2+
sensitivity, but inhibited the contractions in pregnant uterine arteries by decreasing
intracellular Ca" mobilization (Zhang et al., 2006). These findings present an intriguing
dichotomy in the mechanisms of PKC in the regulation of uterine artery contractility at
different physiological states, i.e., pregnancy and nonpregnancy. It is not known to what
extent that the thick- and/or thin-filament regulatory pathways contribute to the dissociate
mechanisms of PKC in the regulation of a 1-adrenoceptor-induced contractions in
nonpregnant and pregnant uterine arteries. The previous finding that the PKC activator
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94-

PDBu decreased phenylephrine-induced Ca mobilization in pregnant uterine arteries
(Zhang et ah, 2006) would suggest an inhibition of the thick filament pathway. This
hypothesis needs to be tested by measuring phosphorylation levels of LC20 in the uterine
arteries.
In addition to the thick filament regulation, previous studies demonstrated the
importance of thin filament regulatory pathway in PKC-mediated regulation of the Ca2+
sensitivity and contractions in the uterine arteries (Xiao et al., 2004, Xiao and Zhang,
2005). Among other mechanisms, caldesmon functions as a thin filament regulatory
protein inhibiting smooth muscle contractions at given levels of [Ca2+]j and LC20
phosphorylation, and phosphorylation of caldesmon reverses its inhibitory effect
(Katsuyama et ah, 1992; Matsumura and Yamashiro, 1993; Morgan and Gangopadhyay,
2001; Wier and Morgan, 2003). In intact vascular smooth muscle, extracellular signalregulated kinase42/44 (ERK42/44) has been demonstrated as a physiologically relevant
caldesmon kinase that mediates caldesmon phosphorylation (Adam et al., 1989). It has been
proposed that ERfLom-mediated phosphorylation of caldesmon reverses the inhibitory
activity of caldesmon on actin-activated myosin ATPase, hence increasing contractions at
2_p

given levels of [Ca ]j and LC20 phosphorylation (Horowitz et al., 1996; Morgan and
Gangopadhyay, 2001). In the uterine arteries, the activation of PKC produced timedependent increases in phosphorylation of ERK42/44 and ERK42/44-dependent
phosphorylation of caldesmon at Ser

7RQ

•

(Xiao et al., 2004). Whether and to what extent

these thin-filament mechanisms contribute to PKC-mediated enhancement of otiadrenoceptor-induced contractions in nonpregnant uterine arteries remain unclear.
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The present study tested the hypothesis that the different effects of PKC activation
on a i-adrenoceptor-induced contractions observed in nonpregnant and pregnant uterine
arteries were due in part to its differential regulations on the thick- and thin-filament
regulatory pathways. To test the hypothesis, we first determined the relation between
tension and LC20 phosphorylation by measuring tension development and
phosphorylation levels of LC20 simultaneously in the same tissue in the presence of
PDBu and phenylephrine. We then determined the role of ERK42/44 in the effect of PKC
on phenylephrine-induced contractions by measuring phosphorylation levels of ERK42/44
and caldesmon-Ser

70Q

#

*

simultaneously with contractions induced by PDBu and

phenylephrine. To determine the cause and effect relation between the activation of
ERK42/44 and PKC’s effect on phenylephrine-induced contractions, we examined the
contractions in the presence of the ERK42/44 inhibitor PD098059. Given that actin
polymerization plays an important role in the thin filament regulatory pathway, we also
examined the effect of cytochalasin B, an inhibitor of actin polymerization, on PKCmediated enhancement of a 1-adrenoceptor-induced contractions in nonpregnant uterine
arteries.
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Materials and Methods

Tissue preparation. Nonpregnant and near-term pregnant (~140 day gestation)
ewes were anesthetized with thiamylal (10 mg/kg), administered via the external left
jugular vein. The ewes were then intubated, and anesthesia was maintained with 1.52.0% halothane in O2 throughout the surgery. An incision was made in the abdomen to
expose the uterus. The uterine arteries were isolated and removed without stretching and
were placed in a modified Krebs’ solution (pH 7.4) of the following composition (in
mM): 115.2 NaCl,4.7 KC1, 1.80 CaCl2, 1.16MgS04, I.I8KH2PO4, 22.14NaHC03, 0.03
EDTA, and 7.88 dextrose. The Krebs’ solution was oxygenated with a mixture of
95%02-5% CO2. The third (nonpregnant) and fourth (pregnant) branches of the main
uterine arteries with similar external diameter were collected and used in the present
studies, as previously described (Zhang et al., 2006). After the tissues were removed,
animals were killed with T-61 euthanasia solution (Hoechst-Roussel; Somerville, NJ). All
procedures and protocols used in the present study were approved by the Animal
Research Committee of Toma Linda University and followed the guidelines in the
National Institutes of Health Guide for the Care and Use ofLaboratoiy Animals.
Simultaneous measurement of tension and LC20 phosphorylation. LC20
phosphorylation and contractile tension were measured simultaneously in the same tissue
of nonpregnant and pregnant uterine arteries, as previously described (Xiao et al., 2004).
Briefly, pregnant and nonpregnant uterine arterial rings were equilibrated in the tissue
bath and the optimal tension was obtained. The tissues were then treated with
phenylephrine in the absence or presence of pretreatment with the PKC activator PDBu

60

•

•

•

94-

for 10 min. In our previous studies of simultaneous measurement of [Ca ]; and
contractions (Zhang et ah, 2006), we demonstrated that pretreatment of PDBu inhibited 3
\iM phenylephrine-induced increase in [Ca2+]i and contractions in pregnant uterine
arteries. In nonpregnant uterine arteries, PDBu had no effect on phenylephrine-induced
contractions at the concentration of 3 pM but potentiated it at lower concentrations of
phenylephrine. To be consistent with the previous studies, the concentrations of
phenylephrine used in the present study were 3 pM and 1 pM for pregnant and
nonpregnant uterine arteries, respectively. As the previous studies demonstrated that 0.1
pM and 1 pM of PDBu produced the maximal effect in nonpregnant and pregnant uterine
arteries, respectively (Zhang et ah, 2006), these concentrations were used for PDBu in the
present study. Tensions developed were continuously recorded with an on-line computer.
To measure phosphorylation levels of LC20 simultaneously in the same tissue, arterial
rings were snap frozen with liquid N2-cooled clamps at the plateau of tension, and were
rapidly immersed in a dry ice-acetone slurry that contained a 10% trichloroacetic acid
(TCA) and 10 mM DTT mixture. Tissues were then stored at -80°C until analysis of
phosphorylated LC20. Tissue LC20 phosphorylation levels were measured as described
previously (Xiao et ah, 2004). Tissues were brought to room temperature in a dry iceacetone-TCA-DTT mixture and washed three times with ether to remove the TCA.
Tissues were then extracted in lOOpl of sample buffer (pH 8.6) that contained 20 mM
Tris base and 23 mM glycine, 8.0 M urea, 10 mMDTT, 10% glycerol, and 0.04%
bromphenol blue. Samples (20pl) of tissue extraction were electrophoresed at 12 mA for
2.5 h after a 30 min prerun in 1.0 mm mini-polyacrylamide gels that contained 10%
acrylamide, 0.27% bisacrylamide, 40% glycerol, and 20 mM Tris base (pH 8.8). Proteins
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were transferred to nitrocellulose membranes and subjected to immunoblot with a specific
monoclonal anti-LC2o antibody (1:500). Goat anti-mouse IgM conjugated with
horseradish peroxidase was used as a secondary antibody (1:2,000). Bands were detected
using enhanced chemiluminescence, visualized on films, and analyzed using Kodak
electrophoresis documentation and analysis system and Kodak ID image analysis
software. Phosphorylated LC20 were expressed as percentage of the intensity of the
phosphorylated LC20 band over the sum of the phosphorylated plus the unphosphorylated
LC20 bands.
Simultaneous measurement of tension and phosphorylation of ERK42/44 and
joq

#

7RQ

caldesmon-Ser . Phosphorylation levels of caldesmon-Ser

and ERK42/44 and

contractions were measured simultaneously in the same tissue of nonpregnant uterine
arteries. Uterine arterial rings were equilibrated in the tissue bath and the optimal tensions
were obtained. Tissues were then subjected to stimulation with 1 pM phenylephrine in
the absence or presence of pretreatment with 0.1 pM PDBu. Tensions developed were
continuously recorded with an on-line computer. To measure phosphorylation levels of
caldesmon-Ser 789 and ERK42/44 simultaneously in the same tissue, arterial rings were snap
frozen at the plateau of tension, as described above. Tissues were then homogenized in
an ice-cold lysis buffer (pH 7.5) that contained Tris-HCl 20 mM, sucrose 250 mM,
EDTA 5 mM, EGTA 5 mM, 0.2% Triton X-100, (3-mercaptoethanol 10 mM,
benzamidine 1 mM, phenylmethylsulfonyl fluoride (PMSF) 1 mM, leupetin 50 pM,
dithiothreitol 1 mM and aprotinin 2 pg/ml. Homogenates were centrifuged at 6,000 g for
5 min at 4 °C and the supernatants were collected. Proteins were determined with a
protein assay kit (Bio-Rad). Samples with 5 pg protein were subjected to electrophoresis
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on 7.5% (phosphorylated caldesmon-Ser789, p-CaD-Ser789) or 10% (phosphorylated
ERK42/44, P-ERX42/44) sodium dodecylsulfate-polyacrylamide gel, and then transferred
electrophoretically to nitrocellulose membranes. The membranes were incubated at room
temperature for 1 h in Tris-buffered saline solution (TBS) that contained 5% dried milk
and 0.5% Tween 20, followed by incubation with primary anti-p-CaD-Ser789 or anti-pERK42/44 antibodies overnight at 4 °C and secondary antibody of anti-rabbit IgG for 1 h at
room temperature. Bands were detected using enhanced chemiluminsecence (ECL),
visualized on Hyperfilm, and analyzed with the Kodak ID image analysis software.
Contraction studies. Nonpregnant uterine arteries were dissected and cut into 2mm ring segments. Isometric tension was measured in the Krebs’ solution in a tissue bath
at 37 °C, as described previously (Zhang et al, 2006). Briefly, tissues were equilibrated
for 60 min and then gradually stretched to the optimal resting tension as determined by
the tension developed in response to 120 mM KC1 added at each stretch level. Contractile
tensions were recorded with an online computer. Tissues were then stimulated with
cumulative additions of phenylephrine in approximate one-half log increments to produce
a concentration-response curve. After washing away phenylephrine, tissues were relaxed
to the baseline and were recovered at the resting tension for 30 min. The second
concentration-response curves of phenylephrine-induced contractions were then repeated
in the presence of PDBu (0.1 pM for 10 min) with or without the ERK inhibitor
PD098059 (10, 30, 60 pM, for 20 min) or the actin polymerization inhibitor cytochalasin
B (5, 10, 30 pM, for 20 min).
Materials. Phenylephrine, PDBu, PD098059, cytochalasin B and monoclonal
anti-LC2o antibody were obtained from Sigma (St. Louis, MO). Anti-p-CaD-Ser 789
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antibody and the secondary antibodies (goat anti-mouse IgM and anti-rabbit IgG
conjugated with horseradish peroxides) were from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-p-ERK42/44 antibody was from Cell signaling Technology (Beverly,
MA). All other electrophoretic and immunoblot reagents were from Bio-Rad (Hercules,
CA). General laboratory reagents were of analytical grade or better, and were purchased
from Sigma and Fisher Scientific. All drug solutions were prepared freshly each day and
kept on ice throughout the experiment.
Data analysis. Data were expressed as means ± SEM. Differences were evaluated
for statistical significance (P < 0.05) using one-way ANOVA followed by Neuman-Keuls
post hoc testing. For the analysis of concentration-response curves, data were analyzed by
computer-assisted nonlinear regression to fit the data using GraphPad Prism (GraphPad
software; San Diego, CA). Values of pD2 (-log EC50) and the maximal response obtained
were used in the statistical analysis.
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Results

Effect of PDBu on phenylephrine-induced LC20phosphorylation and
contractions. Fig. 1 shows the effects of PDBu on phenylephrine-induced LC20
phosphorylation and contractions, measured simultaneously in the same tissue, in
nonpregnant and pregnant uterine arteries. In both nonpregnant and pregnant uterine
arteries, phenylephrine induced contractions with corresponding increases in LC20
phosphorylation in the same tissue. In contrast, PDBu increased contractions in the
absence of any significant changes of phosphorylation levels of LC20. These findings
were consistent with the previous results that showed LC20 phosphorylation-dependent,
and -independent contractions caused by phenylephrine and PDBu, respectively, in the
uterine arteries (Xiao and Zhang, 2005). In pregnant uterine arteries, PDBu significantly
decreased phenylephrine-induced contractions from 70.9±6.6to45.5±6.5%K
maximum (P < 0.05), with a corresponding reduction of phenylephrine-induced LC20
phosphorylation levels from 30.7 ± 1.8 to 13.5 ± 1.7 % (P < 0.05) (Fig. 1). In contrast, in
nonpregnant uterine arteries, PDBu significantly enhanced phenylephrine-induced
contractions from 10.5 ± 2.4 to 54.0 ± 15.8 % K+maximum (P < 0.05), consistent with
the previous finding (Zhang et al., 2006). However, phenylephrine-induced
phosphorylation levels of LC20, measured simultaneously in the same tissue, were not
significantly affected with PDBu (Fig. 1).
Effect of PDBu on phenylephrine-induced contractions and phosphorylation of
ERK42/44 and caldesmon-Ser 789. The findings that PDBu inhibited phenylephrine-induced
94-

Ca mobilization (Zhang et al., 2006) and LC20 phosphorylation (the present finding,
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Fig. 1) in the pregnant uterine arteries, indicate that the inhibition of phenylephrineinduced contractions by PDBu is primarily mediated by its down-regulation of Ca dependent thick-filament regulation in the pregnant uterine arteries. In contrast, the finding
in nonpregnant uterine arteries that PDBu enhanced phenylephrine-induced contractions
in the absence of changes in LC20 phosphorylation suggests a thin filament mechanism.
Thus we further determined the role of ERK activation as a thin filament mechanism in
PDBu-mediated potentiation of phenylephrine-induced contractions in nonpregnant
uterine arteries. Phenylephrine-induced contractions and phosphorylation of ERK42/44 and
caldesmon-Ser 789 were measured simultaneously in the same tissue. Fig. 2 shows that 0.1
pM PDBu and 1 pM phenylephrine alone had no significant effects on phosphorylation
levels of ERK42/44. However, pretreatment of tissues with PDBu resulted in significant
increases in phenylephrine-induced phosphorylation of ERK44(1.9 ± 0.2 to 4.6 ± 0.7 fold
of control, P < 0.05) and ERK42 (1.7 ± 0.2 to 4.9 ± 0.3 fold of control, P < 0.05),
respectively (Fig. 2). These corresponded with a comparable increase in phenylephrineinduced contractile tension, measured simultaneously in the same tissue (Fig. 2).
•
Phosphorylation
levels of caldesmon-Ser789 , measured in the same tissue, were shown in

Fig. 3. PDBu and phenylephrine significantly increased caldesmon-Ser 789
phosphorylation levels 3.0 ± 0.2 fold (P < 0.05) and 3.9 ± 0.3 fold (P < 0.05),
respectively. In addition, PDBu significantly increased phenylephrine-induced
phosphorylation levels of caldesmon-Ser789 (Fig. 3).
Effect of inhibition of ERK42/44 and actin polymerization on PDBu-potentiated
phenylephrine-induced contractions. The finding that PDBu significantly increased
phenylephrine-induced phosphorylation of ERK42/44 that correlated with the increased
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tension development (Fig. 3) suggests a role for ERK42/44 as a thin filament mechanism in
PDBu-mediated potentiation of phenylephrine-induced contractions. To determine the
cause and effect relation, we examined the effect of ERK42/44 inhibition on PDBumediated potentiation of phenylephrine-induced contractions in nonpregnant uterine
arteries. Fig. 4 shows that phenylephrine produced concentration-dependent contractions
of nonpregnant uterine arteries. In the presence of 0.1 pM PDBu, the concentrationresponse curve of phenylephrine-induced contractions was markedly shifted to the left
with a significant increase in the pD2 value from 5.2 ± 0.1 to 7.7 ± 0.3 (P < 0.05),
representing an over 300-fold increase in the potency of phenylephrine-induced
contractions. Pretreatment of tissues with the ERK inhibitor PD098059 (10, 30, and 60
pM) produced a concentration-dependent inhibition of PDBu-mediated potentiation of
phenylephrine-induced contractions (Fig. 4). Given that actin polymerization may play an
important role in PKC/ERICoAM-mediated thin filament regulation, we also examined the
effect of cytochalasin B, an inhibitor of actin polymerization, on PDBu-mediated
enhancement of phenylephrine-induced contractions in nonpregnant uterine arteries. As
shown in Fig. 5, pretreatment of tissues with cytochalasin B (5, 10, and 30 pM) produced
a concentration-dependent inhibition of PDBu-mediated potentiation of phenylephrineinduced contractions.
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Discussion

The present study examined the mechanisms of PKC in its differential
regulations of a i-adrenoceptor-induced contractions in nonpregnant and pregnant uterine
arteries, and offers the following new findings: 1) activation of PKC inhibits ociadrenoceptor-induced contractions in the pregnant uterine artery through a downregulation of Ca2+-dependent thick-filament pathway with decreased phosphorylation
levels of LC20; 2) PKC activation enhances a 1-adrenoceptor-induced contractions in the
nonpregnant uterine artery primarily through thin filament regulatory mechanisms in the
absence of changes in LC20 phosphorylation; 3) activation of ERK42/44 is an important
thin filament mechanism in PKC-mediated potentiation of a 1-adrenoceptor-induced
contractions in the nonpregnant uterine artery; and 4) actin polymerization plays an
important role in PKC/ERK^m-mediated thin filament regulation of a 1-adrenoceptorinduced contractions in the nonpregnant uterine artery.
We have previously demonstrated that activation of PKC enhances ajadrenoceptor-induced contractions in nonpregnant uterine arteries by increasing the Ca2+
sensitivity, but inhibits the contractions in pregnant uterine arteries by decreasing
intracellular Ca2+ mobilization (Zhang et ah, 2006). The present follow-up study
attempted to elucidate the role of the thick- and/or thin-filament regulatory pathways that
contribute to the dichotomy of PKC mechanisms in the regulation of a 1-adrenoceptorinduced contractions in nonpregnant and pregnant uterine arteries. In the uterine artery,
a 1-adrenoceptor-mediated contractions are regulated through both thick-filament
regulatory pathway {i.e. LC20 phosphorylation dependent) and thin-filament regulatory
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pathway {i.e. LC20 phosphorylation independent) (Xiao et ah, 2004, Xiao and Zhang,
2005). In agreement with the previous findings, the present study showed that
phenylephrine induced contractions with corresponding increases in phosphorylation of
LC20 in both pregnant and nonpregnant uterine arteries. In contrast, PDBu produced
contractions in the absence of significant changes in LC20 phosphorylation in the uterine
arteries. This is consistent with the previous studies that demonstrated dissociation
between LC20 phosphorylation and tension development in response to phorbol esters in
vascular smooth muscle including the uterine arteries (Fujiwara et ah, 1988; Sutton and
Haeberle, 1990; Laporte et ah, 1994; Xiao and Zhang, 2005). Most importantly, the
present study showed that PDBu-mediated inhibition of phenylephrine-induced
contractions in pregnant uterine arteries was associated with a significant decrease in
phosphorylation of LC20, measured simultaneously in the same tissue, but PDBu
potentiated phenylephrine-induced contractions in nonpregnant uterine arteries in the
absence of any significant changes in LC20 phosphorylation. Given the previous finding
9+

that PDBu inhibited a 1-adrenoceptor-mediated increases in [Ca ]i in pregnant uterine
arteries (Zhang et ah, 2006), the present study suggests that the inhibitory effect of PKC
activation on a 1-adrenoceptor-induced contractions in pregnant vessels was mediated by
2_j_

suppressing the Ca -dependent thick-filament pathway. The finding of the dissociation
between LC20 phosphorylation and PDBu-mediated increases in phenylephrine-induced
contractions in nonpregnant arteries indicates a thin filament mechanism in the PKCmediated regulation of a 1-adrenoceptor-induced contractions in nonpregnant uterine
arteries. The finding that PKC has differential regulatory effects on thick- and thinfilament pathways in a 1-adrenoceptor-induced contractions in nonpregnant and pregnant
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uterine arteries is intriguing, and provides insights in understanding adaptation of uterine
vascular contractile mechanisms in pregnancy. Consistent with the present study,
previous studies suggested a transition from thin filament to thick filament regulatory
mechanisms in the uterine artery during pregnancy, and that the Ca2d--dependent thickfilament pathway, i.e. changes in LC20 phosphorylation, predominated in ociadrenoceptor-mediated contractions in pregnant uterine arteries (Annibale et ah, 1989,
1990; Xiao et al., 2004; Xiao and Zhang, 2005).
The present finding that PDBu significantly increased phenylephrine-induced
phosphorylation of ERK42/44 that correlated with the increased tension development,
measured simultaneously in the same tissue, suggests a role for ERK42/44 activation as a
thin filament mechanism in PDBu-mediated potentiation of phenylephrine-induced
contractions in nonpregnant uterine arteries. Activation of ERK42/44 is dependent on a
1OC

dual-phosphorylation on Tyr

1QH

and Thr

by mitogen-activated/extracellular-regulated

kinase kinase or MEK (Anderson et al., 1990). ERK42/44 has been proposed to regulate
smooth muscle contractions (Adam et al., 1995; Katoch and Moreland, 1995; Watts,
1996; Dessy et al., 1998; Xiao and Zhang, 2002; Zhao et al., 2003). In intact vascular
smooth muscle, ERK has been demonstrated as a physiologically relevant caldesmon kinase
that mediates caldesmon phosphorylation (Adam et al., 1989). Caldesmon functions as a
thin filament regulatory protein and exerts an inhibitory effect on vascular smooth muscle
contractions (Nagi and Walsh, 1984; Earley et al., 1998; Morgan and Gangopadhyay,
2001). It has been proposed that ERK-mediated phosphorylation of caldesmon reverses the
inhibitory activity of caldesmon on actin-activated myosin ATPase, hence activating the thin
filament pathway (Horowitz et al., 1996; Morgan and Gangopadhyay, 2001). The finding
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that low concentrations of PDBu (0.1 jaM) and phenylephrine (1 pM) alone produced
small but not significant increases in ERK42/44 phosphorylation, but increased caldesmon
phosphorylation at the ERK42/44-specific site Ser

70Q

is intriguing, and suggests a typical

phenomenon that small signal is amplified through the intracellular signaling cascades.
Most importantly, the present study demonstrated that PDBu was able to enhance
phenylephrine-induced phosphorylation of both ERK44/42 and caldesmon-Ser789 and
contractions in the same tissue. The cause and effect relation between activation of
ERK42/44 and the enhancement of contractions in PKC-mediated effect was demonstrated
with the present study showing that inhibition of ERK42/44 with PD098059 abolished
PDBu-mediated increases in phenylephrine-induced contractions. Previous studies
demonstrated that PD098059 inhibited phosphorylation of ERK44/42 and caldesmon-Ser789
in the uterine artery (Xiao et ah, 2004). It should be noted that although only
phosphorylation of caldesmon-Ser

700

was determined in the present study because of the

availability of the antibody, caldesmon can be phosphorylated at several other sites. It has
been shown that PKC phosphorylates sheep aorta caldesmon both in native thin filaments
and in the isolated state at multiple sites of Ser127, Ser587, Ser600, Ser637, Ser 686 and Ser726,
and PKC-mediated phosphorylation of both intact caldesmon and of its C-terminal
fragment containing 658-756, significantly decreases its ability to inhibit acto-heavy
meromyosin ATPase (Vorotnikov et al., 1994). Whether and to what extent these
phosphorylation sites contribute to PKC-mediated potentiation of a 1-adrenoceptorinduced contractions in the uterine arteries remains an intriguing question for further
studies.
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In addition to its role in inhibiting actin-activated myosin ATPase, caldesmon has
been shown to be important in maintaining actin filament stability and inhibiting Arp2/3dependent actin polymerization (Galazkiewicz et al., 1989; Matsumura and Yamashiro,
1993; Yamakita et ah, 2003; Hai and Gu, 2006). The inhibitory effect of caldesmon on
actin polymerization can be reversed by phosphorylation with either ERK44/42 or cdc2
kinase (Yamakita et al., 2003; Hai and Gu, 2006). In addition, ERK44/42 can phosphorylate
an actin-binding protein, cortactin, resulting in activation of the Arp2/3 complex and
actin polymerization (Martinez-Quiles et al., 2004). It has been demonstrated that the
polymerization of actin filaments from monomeric globular actin (G-actin) to filamentous
actin (F-actin), occurring independent of changes in intracellular Ca2+ concentrations and
LC20 phosphorylation, is an important cellular mechanism of thin filament regulation in
smooth muscle contraction (Jones et al., 1999; Metha and Gunst, 1999; Gunst and
Fredberg, 2003; Ozaki et al., 2004), including contractions induced by PDBu and ociadrenoceptor agonists (Nunes, 2002; Tang and Tan, 2003; Zhao et al., 2004; Chen et al.,
2006). The present finding that inhibition of actin polymerization with cytochalasin B
produced a concentration-dependent inhibition of PDBu-mediated potentiation of
phenylephrine-induced contractions in nonpregnant uterine arteries suggests a thin
filament mechanism of actin polymerization in PKC-mediated regulation of otiadrenoceptor-induced contractions. It has been demonstrated that the inhibition of
contractions by actin polymerization inhibitors does not result from the disruption of thickfilament regulatory pathway (Metha and Gunst, 1999; Obara and Yabu, 1994).
In summary, the present study demonstrated that PKC activation by PDBu
differentially regulated a 1-adrenoceptor-mediated thick- and thin- filament pathways and
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resulted in the opposite effects on a i-adrenoceptor-mediated contractions in pregnant and
nonpregnant uterine arteries. The findings of an transition from a thin- to thick filament
mechanism in PKC-mediated regulation of ai-adrenoceptor-induced contractions in
nonpregnant and pregnant uterine arteries and a predominant inhibitory effect of PKC on
a i-adrenoceptor-mediated, Ca -dependent thick-filament regulatory pathway in the
pregnant uterine arteries, provide insights into the adaptation of uterine artery contractile
mechanisms in pregnancy. Further studies are needed to investigate the mechanisms of
steroid hormones in PKC-regulated a i-adrenoceptor signaling pathways in the uterine
arteries and their adaptation to pregnancy.
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Figure 1. Effect of PDBu on phenylephrine-induced LC20 phosphorylation and
contractions in nonpregnant and pregnant uterine arteries. PDBu and/or
phenylephrine (PE)-induced LC20 phosphorylation and contractions were measured
simultaneously in the same tissues as described in the Methods. Top panel and middle
panels: Phosphorylated (P-LC20) and unphosphorylated (unp-LC2o) LC20 were detected
by Western immunoblotting and levels of P-LC20 are expressed as percentage of P-LC20/
(P-LC20+ unp-LC2o). Bottom Panel: Simultaneously measured contractions are
expressed as percentage of 120 mM KCl-induced contraction (% K+). Data are means ±
SEM of tissues from 4 animals, a: P < 0.05, vs. control, b: P<0.05, vs. phenylephrine
treatment alone.
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Figure 2. Effect of PDBu on phenylephrine-induced phosphorylation of ERK42/44
and contractions in nonpregnant uterine arteries. PDBu and/or phenylephrine (PE)induced phosphorylation of ERK42/44 and contractions were measured simultaneously in
the same tissue as described in the Methods. Top and middle panels: Phosphorylated
ERK42 and ERK44 (P-ERK42 and P-ERK44) were detected by Western immunoblotting.
The levels of P-ERK42 and P-ERK44 induced by PDBu and / or phenylephrine are
expressed as fold of control. Bottom Panel: Simultaneously measured contractions are
expressed as percentage of 120 mM KCl-induced contraction (% K+). Data are means ±
SEM of tissues from 4 animals, a: P < 0.05, vs. control, b: P < 0.05, vs. PDBu plus
phenylephrine treatment.
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Figure 3. Effect of PDBu on phenylephrine-induced phosphorylation of caldesmonSer789 in nonpregnant uterine arteries. PDBu and/or phenylephrine (PE)-induced
phosphorylation levels of caldesmon-Ser789 were measured in the same tissues collected
in Fig. 2. Phosphorylated caldesmon-Ser789 (p-CaD-Ser789) was detected by Western
immunoblotting and expressed as fold of control. Data are means ± SEM of tissues from
4 animals, a: P < 0.05, vs. control, b: P < 0.05, vs. PDBu plus phenylephrine treatment.
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Figure 4. Effect of ERK inhibition on PDBu-potentiated phenylephrine-induced
contractions in nonpregnant uterine arteries. Panel A. Effect of PDBu and/or ERK
inhibitor PD098059 (10, 30, 60 jaM) on concentration-response curves of phenylephrineinduced contractions. Panel B. Data analysis of the pD2 values and the maximal
responses (Tmax) of phenylephrine-induced contractions. Phenylephrine-induced
contractions are expressed as percentage of 120 mM KCl-induced contraction (% K+).
Data are means ± SEM of tissues from 5~9 animals, a: P < 0.05, vs. control, b: P < 0.05,
vs. PDBu alone.
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Figure 5. Effect of inhibition of actin polymerization on PDBu-potentiated
phenylephrine-induced contractions in nonpregnant uterine arteries. Panel A. Effect
of PDBu and/or actin polymerization inhibitor Cytochalasin B (5, 10, 30 pM) on
concentration-response curves of phenylephrine-induced contractions. Panel B. Data
analysis of the pD2 values and the maximal responses (Tmax) of phenylephrine-induced
contractions. Phenylephrine-induced contractions are expressed as percentage of 120 mM
KCl-induced contraction (% K+). Data are means ± SEM of tissues from 5~9 animals, a:
P < 0.05, vs. control, b: P < 0.05, vs. PDBu alone.
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CHAPTER FOUR

ROLE OF PKC ISOZYMES IN THE REGULATION OF on-ADRENOCEPTOR MEDIATED CONTRACTIONS IN THE UTERINE ARTERIES

Hongying Zhang and Lubo Zhang

This chapter was submitted for publication to Journal of Pharmacology and Experimental
Therapeutics.
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Abstract

Previously we demonstrated that activation of protein kinase C (PKC) enhanced
a i-adrenoceptor-induced contractions in nonpregnant uterine arteries (NPUA), but
inhibited the contractions in pregnant uterine arteries (PUA). The present study tested the
hypothesis that differential regulation of PKC isozyme activities contributes to the
different effects of PDBu on ai-adrenoceptor-mediated contractions between the pregnant
and nonpregnant uterine arteries. Phenylephrine-induced contractions of ovine NPUA
and PUA were detennined in the absence or presence of the PKC activator phorbol 12,
13-dibutyrate (PDBu), and/or conventional and novel PKC isozymes inhibitor
GF109203X, PKC isozyme-selective inhibitory peptides for conventional PKCs, PKCpI,
PKCpII and PKCs. GF109203X produced a concentration-dependent inhibition of
phenylephrine-induced contractions in both NPUA and PUA, and reversed the PDBumediated potentiation and inhibition of phenylephrine-induced contractions in NPUA and
PUA, respectively. In addition, PKCpI, PKCpII and PKCs inhibitory peptides blocked
the PDBu-mediated responses in both NPUA and PUA. Western blot analysis showed
that PDBu induced a membrane translocation of PKCa, pi, pH and s in PUA, and PKCpI,
pH and s in NPUA. The results disprove the hypothesis that the dichotomy of PKC
mechanisms in the regulation of a i-adrenoceptor-induced contractions in nonpregnant
and pregnant uterine arteries is caused by the activation of different PKC isozymes, and
suggest down-stream mechanisms of differential subcellular distributions for the distinct
functional effects of PKC isozymes in the adaptation of uterine arteries to pregnancy.
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Introduction
During pregnancy, the uterine artery maintains low resistance to accommodate the
large increase in uteroplacental blood flow to ensure normal fetal development. Several
mechanisms are involved in the adaptation of uterine artery contractility during pregnancy
(Ford, 1995; Rosenfeld, 2001; Xiao and Zhang, 2002; Bird et ah, 2003; Xiao and Zhang,
2005). Activation of ai-adrenoceptors is an important mechanism in the regulation of
uterine artery smooth muscle contractions (Magness and Rosenfeld, 1986; Stjernquist and
Owman, 1990; Ford, 1995; Zhang et al., 1995; Cox et al., 2004). Protein kinase C (PKC)
plays a key role in ai-adrenoceptor-mediated contractions of vascular smooth muscle
(Mirmeman, 1988; Nishizuka, 1992; Ford, 1995) and pressure-dependent myogenic tone
of the uterine artery (Xiao and Zhang, 2002; Xiao and Zhang, 2005; Xiao et al., 2006).
Recently we have demonstrated that activation of PKC by phorbol-12, 13-dibutyrate
(PDBu) potentiates ai-adrenoceptor-induced contractions in nonpregnant uterine arteries,
but inhibits the contractions in pregnant uterine arteries (Zhang et al., 2006). In addition,
we have shown that differential regulations of the thick and thin filament pathways play
an important role in the dichotomy of PKC mechanisms in the regulation of aiadrenoceptor-induced contractions in nonpregnant and pregnant uterine arteries (Zhang
and Zhang, under review). However, it remains unknown whether and to what extent
activation of differential PKC isozymes contributes to these pregnancy-specific effects of
PDBu observed in the uterine arteries.
PKC, a serine/threonine kinase family, consists of at least 11 isozymes that are
further classified into three subfamilies: the conventional isozymes (PKCa, P, y), the
novel isozymes (PKC8, 8, q, 0), and the atypical isozymes (PKC^, i, X). We have recently
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demonstrated that PKCoc, P, 5, e, and ^ isozymes express in ovine uterine arteries, with
significantly increased expression levels of PKCp and PKC^, but decreased PKCa and
the basal activity of PKCs in pregnant arteries, as compared with nonpregnant vessels
(Zhang et ah, 2006). Each PKC isozyme has unique enzymatic properties, substrates,
functions, and sub-cellular distributions in different blood vessels and species (Khalil et
ah, 1992; Nishizuka, 1992; Liou and Morgan, 1994; Horowitz et ah, 1996b; Kanashiro
and Khalil, 1998; Kanashiro and Khalil, 2001). Despite extensive studies, the
physiological role of each individual PKC isozymes in the regulation of vascular
contractility, including the uterine artery, remains unclear, which is likely due to a lack of
highly selective pharmacological agents to either inhibit or activate the isozymes. The
majority of available pharmacological compounds act on more than one PKC isozyme
and on other protein kinase(s). Synthesized aminoalkyl bisindolylmaleimide, GF109203X
has been demonstrated to be a potent and selective inhibitor of PKC over other protein
kinases and has been widely used as a tool to explore the role of PKC in particular signal
transduction pathway (Toullec et al., 1991). GF109203X selectively inhibits activity of
conventional and novel PKC isozymes (Gailly et al., 1997; Damron et al., 2002; Nakano
et al., 2004) and decreases their agonist-induced translocation (Giardina et al., 2001;
Sirous et al., 2001; Chu et al., 2003). More recent discovery of PKC isozyme-selective
inhibitory peptides (Csukai and Mochly-Rosen, 1999) allows determining the function of
particular individual PKC isozyme. Following activation, each PKC isozyme translocates
to its unique subcellular sites and binds to isozyme-specific anchoring proteins, receptors
for activated C-kinase (RACKs). Each isozyme has a specific RACK-selective binding
site that is exposed only after the activation of PKC. PKC isozyme-selective inhibitory
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peptides, containing isozyme-specific RACK-binding sites, have been demonstrated to
inhibit translocation of the corresponding isozymes and consequently inhibit their
isozyme-unique function in cardiac myocytes and cerebral arteries (Csukai and MochlyRosen, 1999; Dorn and Mochly-Rosen, 2002; Bright and Mochly-Rosen, 2005).
The present study tested the hypothesis that differential regulation of PKC
isozyme activities contributes to the different effects of PDBu on ai-adrenoceptormediated contractions between the pregnant and nonpregnant uterine arteries.
Concentration-response curves of phenylephrine-induced contractions of the uterine
arteries were conducted in the absence or presence of the PKC activator PDBu and/or the
PKC inhibitor GF109203X, PKC isozyme-selective inhibitory peptides. In addition, the
PDBu-mediated PKC isozyme translocations were determined in the uterine arteries.
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Methods

Tissue preparation. Nonpregnant and near-term pregnant (-140 day gestation)
ewes were anesthetized with thiamylal (10 mg/kg), administered via the external left
jugular vein. The ewes were then intubated, and anesthesia was maintained with 1.52.0% halothane in O2 throughout the surgery. An incision was made in the abdomen to
expose the uterus. The uterine arteries were isolated and removed without stretching and
were placed in a modified Krebs’ solution (pH 7.4) of the following composition (in
mM): 115.2 NaCl, 4.7 KC1, 1.80 CaCl2, 1.16MgS04, I.I8KH2PO4, 22.14NaHC03, 0.03
EDTA, and 7.88 dextrose. The Krebs’ solution was oxygenated with a mixture of
95%02-5% CO2. After the tissues were removed, animals were killed with T-61
euthanasia solution (Hoechst-Roussel; Somerville, NJ). All procedures and protocols
used in the present study were approved by the Animal Research Committee of Loma
Linda University and followed the guidelines in the National Institutes of Health Guide
for the Care and Use of Laboratory Animals.
Contraction studies. The third (nonpregnant) and fourth (pregnant) branches of
the main uterine arteries with similar external diameter were used in the present studies,
as previously described (Zhang et al., 2006). Uterine arteries were dissected and cut into
2-mm ring segments. Isometric tension was measured in the Krebs’ solution in a tissue
bath at 37 °C as described previously (Zhang et al., 2006). Briefly, each ring was
equilibrated for 60 min and then gradually stretched to the optimal resting tension as
determined by the tension developed in response to 120 mM KC1 added at each stretch
level. Tissues were then stimulated with cumulative additions of phenylephrine in
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approximate one-half log increments to generate a concentration-response curve, and
contractile tensions were recorded with an online computer. After washing away
phenylephrine, tissues were relaxed to the baseline and were recovered at the resting
tension for 30 min. The second concentration-response curves of phenylephrine-induced
contractions were then repeated in the absence or presence of GF109203X (0.1, 0.3, and
1 pM for 20 min), PKC isozyme-selective inhibitory peptides for conventional PKCs,
PKCpI, pH or s (3 pM for 20 min) and/or PDBu (30, 100 nM for nonpregnant uterine
arteries, and 0.3, 1 pM for pregnant uterine arteries, for 10 min).
Measurement of PKC isozymes translocation. PDBu-stimulated PKC isozymes
translocation and contractions were measured simultaneously in the same uterine arteries.
Pregnant and nonpregnant uterine artery rings were equilibrated in the tissue bath and the
optimal tensions were obtained. Tissues were then subjected to stimulation with PDBu
(0.2 pM for nonpregnant, 1 pM for pregnant) for 10 min. At the end of treatment, the
tissues were quickly frozen in liquid N2 and cytosolic and particulate fractions were
prepared as described previously (Zhang et al., 2006). Briefly, the tissues were
homogenized in ice-cold homogenization buffer A containing Tris-HCl 20 mM, sucrose
250 mM, EDTA 5 mM, EGTA 5 mM, p-mercaptoethanol 10 mM, benzamidine 1 mM,
phenylmethylsulfonyl fluoride (PMSF) 1 mM, leupetin 50 pM, dithiothreitol 1 mM and
aprotinin 2 pg/ml, pH 7.5. The homogenates were centrifuged at 100,000 g for 20 min at
4 °C, and the supernatants were collected and used as the cytosolic fraction. The pellets
were re-suspended in homogenization buffer A containing 1% triton X-100 by stirring for
overnight at 4 °C, diluted with the buffer A to a final concentration of 0.2% triton X-100,
and then centrifuged at 100,000 g for 20 min at 4 °C. The supernatants were collected and
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referred to as the particulate fraction. Protein concentrations were determined with a
protein assay kit (Bio-Rad). Protein samples (5 pg) of particulate fractions were subjected
to electrophoresis on 7.5% sodium dodecylsulfate-polyacrylamide gel, and then
transferred electrophoretically to nitrocellulose membranes. The membranes were
incubated at room temperature for 1 h in Tris-buffered saline solution (TBS) containing
5% dried milk and 0.5% Tween 20, followed by incubation with primary anti-PKC
isozyme antibodies overnight at 4 °C and secondary antibody for 1 h at room
temperature. Polyclonal antibodies to PKCa, pi, pnand s were used. Bands were detected
with enhanced chemiluminsecence (ECL), visualized on Hyperfilm, and analyzed with
the Kodak ID image analysis software. To normalize the loading variation of each
sample, the corresponding actin level presented in each sample was determined by using
monoclonal anti-actin as primary antibody.
Materials. Phenylephrine, PDBu, GF109203X and anti-actin antibody were
obtained from Sigma (St. Louis, MO). Anti-PKC isozyme antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). The PKC isozyme-selective inhibitory peptides
for conventional PKCs, PKCpi, pn and 8 were from KAI pharmaceuticals (South San
Francisco, CA). All electrophoretic and immunoblot reagents were from Bio-Rad.
General laboratory reagents were of analytical grade or better and were purchased from
Sigma and Fisher Scientific. All drugs were prepared freshly each day and kept on ice
throughout the experiment.
Data analysis. Concentration-response curves were analyzed by computerassisted nonlinear regression to fit the data using GraphPad Prism (GraphPad software;
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San Diego, CA). Results were expressed as means ± SEM. Differences were evaluated
for statistical significance (P < 0.05) by one-way ANOVA and Student’s Mest.
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Results

Effect of GF109203X on phenylephrine-induced contractions. Fig. 1 shows that
phenylephrine produced concentration-dependent contractions of uterine arteries from
both nonpregnant and pregnant ewes. In both nonpregnant and pregnant uterine arteries,
GF109203X (0.1, 0.3, 1 pM), a selective inhibitor for conventional and/or novel PKC
isozymes, produced a concentration-dependent inhibition of phenylephrine-induced
contractions. In the presence of 1 pM GF109203X, the concentration-response curve of
phenylephrine-induced contractions in nonpregnant uterine artery was shifted to the right
with a significant decrease in the pD2 value from 5.48 ± 0.15 to 4.79 ± 0.10 (P < 0.05).
The maximal responses of phenylephrine-induced contractions were not affected with
GF109203X (Fig. 1 & Fig. 2). In pregnant uterine arteries, 0.3, 1 pM GF109203X shifted
the concentration-response curve of phenylephrine-induced contractions to the right with
a significant decrease in the pD2 values from 6.26 ± 0.07 to 5.77 ± 0.02, and from 6.20 ±
0.08 to 5.40 ± 0.02, respectively (P < 0.05). The maximal responses of phenylephrineinduced contractions were significantly decreased from 185.20 ± 5.73 to 172.33 ± 1.72 %
K+ maximum (P < 0.05) in the presence of 1 pM GF109203X (Fig. 1 & Fig. 2).
Effect of GF109203X on PDBu-affectedphenylephrine-induced contractions.
Our previous study demonstrated that PDBu suppressed phenylephrine-induced
contractions in pregnant uterine arteries, but potentiated the contractions in nonpregnant
uterine arteries (Zhang et ah, 2006). To determine whether the effect of PDBu on
phenylephrine-induced contractions in uterine arteries is through the activation of PKC,
the PDBu-mediated responses were determined in the absence or presence of
GF109203X in nonpregnant and pregnant uterine arteries. Consistent with the previous
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findings, Fig. 3 shows that in pregnant uterine arteries, PDBu (0.3 and 1 pM) dosedependently inhibited phenylephrine-induced contractions, with marked decreases in the
maximal response. GF109203X significantly inhibited the PDBu-mediated response and
reversed its effect on phenylephrine-induced maximal response in the pregnant uterine
arteries (Fig. 3). In the presence of 1 pM GF109203X and 0.3 pM or 1 pM PDBu,
respectively, the pD2 values of phenylephrine-induced contractions were not significantly
different from each other (5.03 ± 0.25 vs. 4.98 ± 0.25, P > 0.05), and were not
significantly different from the pD2 value of phenylephrine-induced contractions in the
presence of 1 pM GF109203X alone (5.40 ± 0.02, P > 0.05), shown in Fig. 1. In
nonpregnant uterine arteries, also consistent with the previous findings (Zhang et al.,
2006), PDBu (30 and 100 nM) produced a concentration-dependent potentiation of
phenylephrine-induced contractions with significant increases in the pD2 values but no
significant effects on the maximal responses (Fig. 4). In the presence of 100 nM PDBu,
the concentration-response curve of phenylephrine-induced contractions was markedly
shifted to the left with a significant increase in the pD2 value from 5.30 ± 0.08 to 8.45 ±
0.34 (P < 0.05), representing a 3-order of magnitude increase in the potency of
phenylephrine-induced contractions. As shown in Fig. 4, in the presence of 1 pM
GF109203X and 0.3 pM or 1 pM PDBu, respectively, the pD2 values of phenylephrineinduced contractions were not significantly different from each other (4.81 ±0.19 vs.
5.05 ± 0.22, P > 0.05), and were not significantly different from the pD2 value of
phenylephrine-induced contractions in the presence of 1 pM GF109203X alone (4.79 ±
0.10, P > 0,05), shown in Fig. 1. The maximal responses of phenylephrine-induced
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contractions were not significantly different among the treatments in nonpregnant uterine
arteries.
Effect of PKC isozyme-selective inhibitory peptides on PDBu-affected
phenylephrine-induced contractions. To determine the cause and effect relations
between individual PKC isozymes and the PDBu-mediated responses, we determined the
effects of PKC isozyme-selective inhibitory peptides for conventional PKCs (cPKCs),
PKCpI, PKCpII and PKCs on PDBu-mediated effects on phenylephrine-induced
contractions in pregnant and nonpregnant uterine arteries. Because these peptides
themselves cannot cross biological membranes, they are modified with conjugation of
peptide carriers via Cys-Cys bonds to facilitate their transportation through biological
membranes into cells. Once in the cells, the Cys-Cys bonds are reduced to enable the exit
of the carriers but trapping the peptides inside the cells (Dorn and Mochly-Rosen, 2002).
As shown in Fig. 5, in both nonpregnant and pregnant uterine arteries, carrier alone had
no significant effects on PDBu-mediated responses on phenylephrine-induced
contractions. In nonpregnant uterine arteries, PDBu with the peptide carrier alone
significantly increased the pD2 of phenylephrine-induced contractions from 5.22 ± 0.07 to
7.39 ± 0.20 (P < 0.05), which was significantly inhibited by PKC isozyme-selective
inhibitory peptides for cPKCs (6.02 ± 0.18), PKCpI (5.47 ± 0.20), PKCpII (5.33 ± 0.31),
and PKCs (5.44 ± 0.36), respectively (P < 0.05 for all, as compared with PDBu plus
carrier alone). In the presence of PKCpI, PKCpII, and PKCs inhibitory peptides,
respectively, the pD2 values of phenylephrine-induced contractions were not significantly
different in the absence or presence of PDBu (Fig. 6). In addition, the maximal responses
of phenylephrine-induced contractions were not significantly different among the
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treatments in nonpregnant uterine arteries (Fig. 6). In pregnant uterine arteries, there were
no significant differences in the pDi values of phenylephrine-induced contractions among
the treatments (Fig. 5 and 6). PDBu with the peptide carrier alone significantly decreased
the maximal response of phenylephrine-induced contractions to 22.5% of control, which
was partially blocked by specific PKCpi (55.3%), PKC(3II (43.8%), and PKC 8 (50.9%)
inhibitory peptides, respectively (P < 0.05 for all, as compared with PDBu plus carrier
alone) (Fig. 5 and 6). In contrast, cPKCs inhibitory peptide had no significant effect on
PDBu-mediated responses in the pregnant uterine arteries.
PDBu-induced translocation of PKC isozymes in uterine arteries. In
nonpregnant uterine arteries, PDBu significantly increased the levels of PKCpI, PKCpII,
and PKCs in membrane particulate fractions to 174.1 ± 23.97%, 358.4 ± 96.86%, and
252.9 ± 84.98% of control (P < 0.05 for all), respectively, without affecting PKCa levels,
suggesting that PDBu induced translocation and activation of PKCpI, PKCpII, and PKCs,
but not PKCa (Fig. 7). In pregnant uterine arteries, PDBu significantly increased the
levels of PKCa, PKCpI, PKCpII, and PKCs in membrane particulate fractions to 237.35
± 33.0%, 329.03 ± 33.47%, 122.29 ± 7.76%, and 666.12 ± 167.70% of control,
respectively (P < 0.05 for all), suggesting that PDBu induces translocation and activation
of all these four PKC isozymes in pregnant uterine arteries.
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Discussion

The present study demonstrated that PKC activation involved in ai-adrenoceptormediated contractions in ovine uterine arteries, and was responsible for the effects of
PDBu on ai-adrenoceptor-mediated contractions of nonpregnant and pregnant uterine
arteries. More importantly, individual isozymes of conventional PKCs, PKCp and PKCe
were identified to be involved in the PDBu-mediated responses.
It has been suggested that PKC play a key role in ai-adrenoceptor-mediated
smooth muscle contractions (Nishimura et ah, 1990; Gailly et ah, 1997; Buus et al., 1998;
Kitazawa et al., 2000; Martinez et al., 2000; Sato et al., 2001). In agreement with the
previous findings, the present study showed that GF109203X, an inhibitor for
conventional and novel PKC isozymes, concentration-dependently inhibited
phenylephrine-induced contractions in both nonpregnant and pregnant uterine arteries,
suggesting a role of conventional and novel PKC isozymes in ai-adrenoceptor-mediated
contractions in the uterine artery. The concentrations of GF109203X used in the present
study are within the range shown to inhibit PKC in the previous studies (Toullec et al.,
1991; Damron et al., 2002; Chu et al., 2003).
Our previous study demonstrated that PDBu inhibited a i-adrenoceptor-mediated
contractions in pregnant uterine arteries (Zhang et al., 2006). In the present study, we
found that PDBu-mediated responses were blocked by GF109203X, suggesting a causeeffect relation between PKC activation and PDBu-mediated inhibitory effects in the
pregnant uterine arteries. The finding that inhibition of PKC has a dual effect on ajadrenoceptor-mediated contractions, i.e., inhibition of a i-adrenoceptor-mediated
contractions and blockade of PDBu-mediated inhibitory effects on ai-adrenoceptor-
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mediated contractions, is intriguing and suggests a two-compartment model of PKC in
the regulation of ai-adrenoceptor-mediated contractions in pregnant uterine arteries. One
compartment of PKC may be tightly associated with ai-adrenoceptors and forms a
“signalsome”, which is activated by phenylephrine and participates in ai-adrenoceptormediated contractions. The other more diffusely distributed compartment locates distal to
ai-adrenoceptors, which is activated non-selectively by phorbol esters and mediates an
inhibitory effect on ai-adrenoceptor-mediated contractions. It has been well demonstrated
that the function of each PKC isozyme depends on the subcellular location and the
availability of protein substrates that can be phosphorylated by the isozyme at the site of
anchoring (Dorn and Mochly-Rosen, 2002).
The other possibility is that different PKC isozymes may be involved in the
regulation of ai-adrenoceptor-mediated responses. GF109203X is a nonselective PKC
inhibitor that blocks both conventional and novel PKC isozymes. We have demonstrated
the presence of PKCa, pi, pH, e, but not y, isozymes in the uterine arteries (Zhang et al.,
2006). In the present study, we have used the selective inhibitory peptides for PKCa, pi,
pH, and £ isozymes to determine the role of PKC isozymes in the PDBu-mediated
responses. The inhibitory activities of these peptides are obtained at an intracellular
concentration of 5-50 nM (Dorn and Mochly-Rosen, 2002). In pregnant uterine arteries,
we found that the inhibitory effect of PDBu on ai-adrenoceptor-induced contractions was
partially, but significantly reversed by inhibition of PKCpI, pH and s, respectively,
suggesting an involvement of these isozymes in the PDBu-mediated inhibitory effect.
Previous studies have shown that overexpression of PKCp inhibits agonist-induced Ca2+
mobilization, and inhibition of PKCp results in a dramatic increase in agonist-mediated
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Ca2+ release (Hua et al., 1993; Vuong et al., 1998; Kang et al., 2001). In addition, it has
been demonstrated that PKCs inhibits L-type Ca2+ current and PKCs inhibition increases
phenylephrine-induced maximal contractions (Hu et ah, 2000; Grimm et al., 2006). Given
our previous finding that PDBu significantly inhibited ai-adrenoceptor-mediated
increases in intracellular Ca2+ concentrations in pregnant uterine arteries (Zhang et al.,
2006), the present results suggest that the inhibitory effect PDBu on ai-adrenoceptormediated contractions in pregnant uterine arteries is caused by activation of PKCpI, pH
and £, resulting in a decrease in ai-adrenoceptor-mediated Ca" mobilization. This is
supported with the finding that PDBu induced a membrane translocation of PKCpI, pH
and s in the uterine artery. It should be noticed that none of these PKC-isozyme selective
peptide inhibitors fully reversed the PDBu-mediated inhibition of phenylephrine-induced
contractions in pregnant uterine arteries. This is possibly due to either not high enough
inhibitor concentrations, or presence of an additive/synergistic effect of PKC isozymes in
the PDBu-mediated response. In contrast to PKCpI, pH, and 8 inhibitor peptides, the
inhibitor peptide for conventional PKCs, including PKCa, p and y, had no significant
effect on PDBu-inhibited phenylephrine-induced contractions. We have demonstrated
previously that PKCy does not express in ovine uterine arteries (Zhang et al., 2006). This
suggests that PKCa does not contribute to the inhibitory effect of PDBu on ap
adrenoceptor-mediated contractions in pregnant uterine arteries. Indeed, the finding that
the conventional PKC isozyme-selective inhibitor peptide that blocks both PKCa and p
had no effect, but PKCp inhibitor peptides partially reversed PDBu-mediated response,
would suggest that PKCa activation by PDBu appears to increase the contraction. This is
supported by the previous findings that PKCa activation induced contractions of vascular
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smooth muscle (Singer et al., 1992; Walsh et ah, 1994; Walsh et ah, 1996). Given our
previous finding of increased expression levels of PKCp and decreased PKCa in
pregnant, as compared with nonpregnant, uterine arteries (Zhang et al., 2006), the present
results suggest that the adaptation of the uterine artery to pregnancy is associated with the
upregulation of the PKC isozymes that inhibit ai-adrenoceptor-mediated contractions, and
the down-regulation of the PKC isozyme(s) that increase ai-adrenoceptor-induced
contractions.
In nonpregnant uterine arteries, it appears that PKC activation has a consistent
and positive regulatory role in ai-adrenoceptor-mediated contractions. GF109203X
inhibited phenylephrine-stimulated contractions and blocked PDBu-mediated potentiation
of phenylephrine-induced contractions, suggesting a single functional compartment of
PKC isozyme(s) in the regulation of ai-adrenoceptor-mediated contractions. Unlike
pregnant uterine arteries, PKCp and s inhibitor peptides produced a near complete
inhibition of PDBu-mediated potentiation of ai-adrenoceptor-induced contractions in
nonpregnant uterine arteries, suggesting that activation of PKCp and 8 contributes in
parallel to the PDBu-mediated effect. Consistent with this finding, PDBu increased the
membrane translocation of PKCpI, pH and s in nonpregnant uterine arteries. The role of
PKCa is not clear at the present, given that PDBu did not increase its membrane
translocation. We have recently demonstrated that PDBu potentiates ai-adrenoceptor9-4-

induced contractions in nonpregnant uterine arteries by increasing the Ca~ sensitivity
(Zhang et al., 2006). Given the previous findings that PKCc and p isozymes regulated
vascular smooth muscle contractions through increasing the Ca2+ sensitivity (Bitar et al.,
1991; Singer et al., 1992; Walsh et al., 1994; Horowitz et al., 1996a; Walsh et al., 1996;
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Dessy et al., 2000), the present study suggests that PDBu activates PKC(3 and s and
increases the Ca sensitivity, resulting in the potentiation of a j-adrenoceptor-induced
contractions in nonpregnant uterine arteries.
The finding that activation of PKCp and s participates in apparent opposite effects
of PDBu on ai-adrenoceptor-induced contractions in nonpregnant and pregnant uterine
arteries, is intriguing and suggests that the dichotomy of PKC mechanisms in the
regulation of a i-adrenoceptor-induced contractions in nonpregnant and pregnant uterine
arteries is not caused by the activation of different PKC isozymes. Although previous
studies have shown that different PKC isozymes have unique enzymatic properties,
substrates, functions in different blood vessels and species (Khalil et al., 1992; Liou and
Morgan, 1994; Horowitz et al., 1996b; Nishizuka, 1992; Kanashiro and Khalil, 1998;
Kanashiro and Khalil, 2001), the present study is the first one to show that activation of
the same PKC isozymes, i.e. PKCp and s, exhibit opposite effects in the same vessel in
different physiological states, i.e. pregnancy and nonpregnancy. This finding suggests the
down-stream mechanisms of PKC isozymes are involved. Because the function of each
PKC isozyme requires localization to the specific subcellular sites such as plasma
membrane, cytoskeletal filaments, or myofilaments, and ability of the isozyme to
phosphorylate substrates co-localized to the sites, the distinct functional effects of the
same PKC isozymes with essentially identical catalytic activity can be achieved by their
binding and proximity to a particular set of substrates (Dorn and Mochly-Rosen, 2002). It
is possible that pregnancy alters the subcellular distribution of PKC isozymes, resulting
in regulating different sets of substrates in the uterine arteries. We have demonstrated that
activation of PKC enhances the contractions in nonpregnant uterine arteries through its
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effects on the thin filament regulatory pathway and activation of ERK/caldesmon and
actin polymerization, but inhibits a i-adrenoceptor-mediated contractions in pregnant
uterine artery through down-regulation of the thick filament pathway and decreased
myosin light chain phosphorylation (Zhang and Zhang, under review). Taken together,
our results suggest a transition of subcellular localization of PKC(3 and 8 from thin
filaments to thick filaments in the uterine arteries during pregnancy. Given the finding
that steroid hormones induced modulation of cytosolic and membrane-bound regulatory
proteins including PKC, and regulate their function (Simoncini et ah, 2000; Kelly and
Levin, 2001; Simoncini et ah, 2002; Tostes et. al, 2003; Orshal and Khalil, 2004), future
studies are needed to investigate the mechanisms of steroid hormones in pregnancyadaptation of PKC isozyme subcellular distribution and its role in the regulation of ociadrenoceptor signaling pathways in the uterine arteries.
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Figure 1. Effect of GF109203X (GF) on concentration-response curves of
phenylephrine-induced contractions in uterine arteries. Phenylephrine-induced
contractions were expressed as percentage of 120 mM KCl-induced response (% K+).
Data are means ± SEM of tissues from 4~10 animals.
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Figure 2. Effect of GF109203X on the pDi values and the maximal response (Tmax)
of phenylephrine-induced contractions in uterine arteries. Data are means ± SEM of
tissues from 4~10 animals. *, P < 0.05, control vs. GF109203X treatment.
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Figure 3. Effect of GF109203X on PDBu-inhibited phenylephrine-induced
contractions in pregnant uterine arteries. Panel A and B show the effect of PDBu (A:
0.3 jaM; B: 1 pM), in the absence or presence of 1 pM GF109203X, on concentrationresponse curves of phenylephrine-induced contractions. The pD2 values and the maximal
response (Tmax) are shown in Panel C and D, respectively. Phenylephrine-induced
contractions were expressed as percentage of 120 mM KCl-induced contraction (% K+).
Data are means ± SEM of tissues from 4 animals, a, P < 0.05, vs. control; b, P< 0.05,
PDBu vs. PDBu plus GF109203X.
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Figure 4. . Effect of GF109203X on PDBu-inhibited phenylephrine-induced
contractions in nonpregnant uterine arteries. Panel A and B show the effect of PDBu
(A: 30 nM; B: 100 nM), in the absence or presence of 1 pM GF109203X, on
concentration-response curves of phenylephrine-induced contractions. The pD2 values
and the maximal response (Tmax) are shown in Panel C and D, respectively.
Phenylephrine-induced contractions were expressed as percentage of 120 mM KC1induced contraction (% K+). Data are means ± SEM of tissues from 4 animals, a, P <
0.05, vs. control; b, P< 0.05, PDBu vs. PDBu plus GF109203X.
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Figure 5. Effect of PKC isozyme-selective inhibitory peptides on PDBu-affected
phenylephrine-induced contractions in uterine arteries. Phenylephrine-induced
contractions were expressed as percentage of 120 mM KCl-induced contraction (% K+).
Data are means ± SEM of tissues from 4 animals.
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Figure 6. . Effect of PKC isozyme-selective inhibitory peptides on pD2 values and
the maximal response (Tmax) of PDBu-affected phenylephrine-induced contractions
in uterine arteries. Data are means ± SEM of tissues from 4 animals, a, P < 0.05, vs.
control; b, P < 0.05, PDBu plus carrier vs. PDBu plus PKC isozyme-selective inhibitory
peptide.
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Figure 7. PDBu-induced membrane translocation of PKC isozymes in uterine
arteries. Membrane translocation of PKC isozymes was measured with Western blotting,
as described in Methods. The results were expressed as percentage of control of each
isozyme, blotted in the same membrane. Data are means ± SEM of tissues from 4
animals. *, P < 0.05, vs. control.
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CHAPTER FIVE
GENERAL SUMMARY

Differential Regulatory Effect of PKC on oii-adrenoceptor-induced Contractions in
the Nonpregnant and Pregnant Uterine Artery
The present research project examined the mechanisms of PKC activation effect
on ai-adrenoceptor-induced contractions in nonpregnant and pregnant uterine arteries,
and offers the following new findings: 1) activation of PKC inhibits ai-adrenoceptorinduced contractions in the pregnant uterine artery through a down-regulation of Ca dependent thick-filament pathway by decreasing Ca mobilization and phosphorylation
levels of LC20; 2) PKC activation enhances a 1-adrenoceptor-induced contractions in the
nonpregnant uterine artery primarily through increasing Ca sensitivity via thin filament
regulatory mechanisms; 3) the expression and activity of PKC isozymes were
differentially regulated in pregnant and nonpregnant uterine arteries, and individual
isozymes of conventional PKCs, PKC(3 and PKCs were identified to be involved in the
PDBu-mediated opposite effects on a 1-adrenoceptor-induced contractions in those
vessels.
It has been suggested that PKC plays an important role in regulating vascular
myogenic response (Davis and Hill, 1999). The recent studies in Dr. Lubo Zhang’s
laboratory have demonstrated that myogenic tone of the uterine artery is reduced during
pregnancy, which is primarily regulated through the PKC signal pathway (Xiao et al.,
2006). In addition to its role in the regulation of myogenic tone, the study in chapter two
demonstrated that activation of PKC interacted with a 1-adrenoceptors and differentially
modulated a 1-adrenoceptor-mediated contractions in the pregnant and nonpregnant
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uterine arteries. Previous studies have demonstrated that PKC can either inhibit or
potentiate ai-adrenoceptor-mediated contractions in different arteries from different
species (Amobi et ah, 1999; Bazan et ah, 1993; Cotecchia et ah, 1985; Danthuluri et ah,
1984; Henrion et ah, 1992; Husain et ah, 2004; Leeb-Lundberg et ah, 1985; Longo et ah,
2000; Martinez et ah, 2001; Matsumura et ah, 2001; McMillan et ah, 1986; Salaices et
ah, 1990). However, it has not been previously demonstrated that activation of PKC can
inhibit and potentiate a i-adrenoceptor-mediated contractions in the same artery of the
same species at different physiological states, i.e. nonpregnant and pregnant. Thus, the
present finding of a potentiation of ai-adrenoceptor-mediated contractions in nonpregnant
uterine arteries, but an inhibition in pregnant uterine arteries provides a physiological
importance of PKC in regulating the adaptation of ai-adrenoceptor-mediated contractions
of the uterine artery during pregnancy.
ai-adrenoceptor-mediated smooth muscle contraction is regulated through
changes in intracellular Ca mobilization and the Ca sensitivity of the contractile
apparatus. Ca mobilization is regulated through Ca“ -dependent thick-filament regulation
(i.e. Ca and LC20 phosphorylation dependent) (Horowitz et ah, 1996b; Pfitzer, 2001).
Regulation of the Ca2+sensitivity of myofilaments is through both Ca2+-independent thickfilament regulatory pathway (i.e. Ca independent but LC20 phosphorylation dependent),
and the thin-filament regulatory pathway (i.e. LC20 phosphorylation independent) (Morgan
and Gangopadhyay, 2001; Somlyo and Somlyo, 2003; Xiao et ah, 2004, Xiao and Zhang,
2005). In the studies of chapter two and three, activation of PKC was found to abolish aiadrenoceptor-induced increase in [Ca2+]i and LC20 phosphorylation in pregnant uterine
arteries, which were accompanied by decreased contractions, measured simultaneously in
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the same tissues. These suggest that the inhibitory effect of PKC activation on ociadrenoceptor-induced contractions in pregnant vessels was mediated predominantly by
suppressing the Ca -dependent thick-filament pathway with decreased Ca mobilization
and consequently decreased LC20 phosphorylation. Consistent with the present finding,
previous studies in ovine cerebral arteries demonstrated that PDBu inhibited
94-

•

norepinephrine-induced increases in intracellular Ca concentrations and contractions
(Longo et ah, 2000). On the other hand, in nonpregnant uterine artery, PKC activation by
94-

PDBu had no effect on a 1-adrenoceptor-mediated Ca mobilization and LC20
phosphorylation but potentiated the simultaneously measured contraction. The dissociation
between LC20 phosphorylation and PDBu-mediated increases in phenylephrine-induced
contractions in nonpregnant arteries indicates a thin filament mechanism of increased
Ca sensitivity in the PKC-mediated regulation of a 1-adrenoceptor-induced contractions
in nonpregnant uterine arteries.
Among other thin filament mechanisms, caldesmon functions as a thin filament
regulatory protein inhibiting smooth muscle contractions at given levels of [Ca ]j and LC20
phosphorylation, and phosphorylation of caldesmon reverses its inhibitory effect
(Katsuyama et al., 1992; Matsumura and Yamashiro, 1993; Morgan and Gangopadhyay,
2001; Wier and Morgan, 2003). ERK42/44, as a physiologically relevant caldesmon kinase
that mediates caldesmon phosphorylation (Adam et al., 1989), has been proposed to
phosphorylate caldesmon and reverse its inhibitory effect on actin-activated myosin
ATPase, hence activating the thin filament pathway (Horowitz et al., 1996; Morgan and
Gangopadhyay, 2001). In the uterine arteries, the activation of PKC produced timedependent increases in phosphorylation of ERK42/44 and ERK42/44-dependent
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phosphorylation of caldesmon at Ser

nOQ

t

(Xiao et ah, 2004). In the studies in chapter

three, the finding that PDBu significantly increased phenylephrine-induced
phosphorylation of ERK42/44, caldesmon-Ser789 and consequently increased tension
development in the same tissue suggests a role for ERK42/44 activation as a thin filament
mechanism in PDBu-mediated potentiation of phenylephrine-induced contractions in
nonpregnant uterine arteries. Meanwhile, the cause and effect relation between activation
of ERK42/44 and the enhancement of contractions in PKC-mediated effect was
demonstrated with the studies in chapter three showing that inhibition of ERK42/44 with
PD098059 abolished PDBu-mediated increases in phenylephrine-induced contractions.
Previous studies demonstrated that PD098059 inhibited phosphorylation of ERK44/42 and
caldesmon-Ser789 in the uterine artery (Xiao et ah, 2004).
The polymerization of actin filaments from monomeric globular actin (G-actin) to
filamentous actin (F-actin), occurring independent of changes in intracellular Ca2+
concentrations and LC20 phosphorylation, plays an important role in the thin filament
pathway to regulate smooth muscle contraction (Jones et ah, 1999; Metha and Gunst,
1999; Gunst and Fredberg, 2003; Ozaki et ah, 2004), including contractions induced by
PDBu and a 1-adrenoceptor agonists (Nunes, 2002; Tang and Tan, 2003; Zhao et ah, 2004;
Chen et ah, 2006). The studies of chaptor three showed that inhibition of actin
polymerization with cytochalasin B produced a concentration-dependent inhibition of
PDBu-mediated potentiation of phenylephrine-induced contractions in nonpregnant
uterine arteries. Given previous finding that the inhibition of contractions by actin
polymerization inhibitors does not result from the disruption of thick-filament regulatory
pathway (Metha and Gunst, 1999; Obara and Yabu, 1994), the present studies suggested a
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thin filament mechanism of actin polymerization in PKC-potentiated a i-adrenoceptorinduced contractions in nonpregnant uterine artery. The increase in actin polymerization
might be related to PDBu-enhanced a i-adrenoceptor-induced phosphorylation of
ERK44/42 and caldesmon-Ser789, because 1) caldesmon has been shown to play and
important role in maintaining actin filament stability and inhibiting Arp2/3-dependent actin
polymerization (Galazkiewicz et al, 1989; Matsumura and Yamashiro, 1993; Yamakita et
ak, 2003; Hai and Gu, 2006); 2) ERK44/42 can phosphorylate caldesmon reverse its
inhibitory effect on actin polymerization (Yamakita et ak, 2003; Hai and Gu, 2006);
3)ERK44/42 can phosphorylate an actin-binding protein, cortactin, resulting in Arp2/3dependent actin polymerization (Martinez-Quiles et ak, 2004).

Role of PKC Isozymes in the Differential Regulation of oci-adrenoceptor-mediated
Contractions in the Uterine Arteries
The apparent opposite effects of PKC on a 1-adrenoceptor-mediated contractions
in nonpregnant and pregnant uterine arteries may be due in part to the differential
regulation of PKC isozymes that show different enzymatic properties, substrates and
functions (Horowitz, 1996b; Khalil, 1992; Liou, 1994). In chapter two, PKC isozyme
expression and sub-cellular distribution were suggested to be differentially regulated in
nonpregnant and pregnant uterine arteries, with significantly increased expression levels
of PKC p and PKC<^, but decreased PKCa and the basal activity of PKCs in pregnant, as
compared with nonpregnant, uterine arteries.
The study in chapter four suggested that there are two possible mechanisms to
explain the inhibitory effect of PDBu on a 1-adrenoceptor-mediated contractions in the
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pregnant uterine arteries. One of the mechanisms is an existence of tow compartments of
PKC in the regulation of ai-adrenoceptor-mediated contractions. One compartment of
PKC may be tightly associated with ai-adrenoceptors and participate in ai-adrenoceptor
agonist -induced contractions. The other compartment locates distal to ai-adrenoceptors
and more diffusely in cytosol, which is activated non-selectively by phorbol esters and
mediates an inhibitory effect on ai-adrenoceptor-mediated contractions. This proposed
two-compartment model of PKC is supported with previous finding that the subcellular
location and the availability of protein substrates of PKC determine the function of each
PKC isozyme (Dorn and Mochly-Rosen, 2002). The other proposed mechanism to
regulate PKC inhibitory effect in the pregnant uterine arteries is that different PKC
isozymes may be involved in the regulation of ai-adrenoceptor-mediated responses. The
results in chapter four suggested that PDBu-mediated inhibition of ai-adrenoceptormediated contractions in pregnant uterine arteries is caused by activation of PKCpI, pH
2_|_

and s, resulting in a decrease in ai-adrenoceptor-mediated Ca" mobilization. In
agreement with this finding, previous studies have shown that PKCp and 8 inhibits
agonist-induced Ca2+ mobilization, and their inhibition results in a respective increase in
agonist-mediated Ca release or maximal contractions (Hu et ah, 2000; Hua et ah, 1993;
Grimm et ah, 2006; Kang et ah, 2001; Vuong et al., 1998). Nevertheless, the role of
PKCa activation by PDBu appears to increase the ai-adrenoceptor-mediated contraction.
Taken together with the finding in chapter two, the present research project suggests that
the adaptation of the uterine artery to pregnancy is associated with the upregulation of the
PKC isozymes (eg. PKCpI and pH) that inhibit ai-adrenoceptor -mediated contractions,
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and the down-regulation of the PKC isozyme (eg. PKCa) that increases ai-adrenoceptorinduced contractions.
In contrast, a single functional compartment of PKC isozyme(s) in the regulation
of ai-adrenoceptor-mediated contractions in nonpregnant uterine arteries was suggested
in the study of chapter four, since PKC inhibitor reduced phenylephrine-stimulated
contractions and blocked PDBu-mediated potentiation of phenylephrine-induced
contractions. Meanwhile, the results in chapter four suggested that PDBu activates PKCp
9-4-

and s and increases the Ca sensitivity, resulting in the potentiation of a i-adrenoceptorinduced contractions in nonpregnant uterine arteries. This finding is supported by previous
suggestion that PKCe and p isozymes regulated vascular smooth muscle contractions
9-4-

through increasing the Ca sensitivity (Bitar et al., 1991; Singer et al., 1992; Walsh et al.,
1994; Horowitz et al., 1996a; Walsh et al., 1996; Dessy et al., 2000). However, the role of
PKCa is not clear at the present, given that PDBu did not increase its membrane
translocation in nonpregnant uterine arteries
The finding that activation of PKCp and s participates in apparent opposite
effects of PDBu on ai-adrenoceptor-induced contractions in nonpregnant and pregnant
uterine arteries, disproves the hypothesis that the dichotomy of PKC mechanisms in the
regulation of a i-adrenoceptor-induced contractions in nonpregnant and pregnant uterine
arteries is caused by the activation of different PKC isozymes. The study in chapter four
was the first one to show that activation of the same PKC isozymes, i.e. PKCp and 8,
exhibit opposite effects in the same vessel in different physiological states, i.e. pregnancy
and nonpregnancy. This finding suggested the down-stream mechanisms of PKC
isozymes are involved. Because the distinct functional effects of the same PKC isozymes
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with essentially identical catalytic activity have been suggested to be achieved by their
binding and proximity to a particular set of substrates (Dorn and Mochly-Rosen, 2002), it
is possible that pregnancy alters the subcellular distribution of PKC isozymes, resulting
in regulating different sets of substrates in the uterine arteries. For example, PKCp and e
have been suggested to decrease agonist-induced Ca mobilization resulting in reduction
of contractions (Hua et ah, 1993; Vuong et ah, 1998; Hu et ah, 2000; Grimm et ah, 2006;
Kang et ah, 2001), or regulate contractions through thin filament pathway with increased
Ca2+ sensitivity (Bitar et ah, 1991; Singer et ah, 1992; Walsh et ah, 1994; Horowitz et ah,
1996a; Walsh et ah, 1996; Dessy et ah, 2000). In addition, the study in chapter three
demonstrated that activation of PKC enhances the contractions in nonpregnant uterine
arteries through its effects on the thin filament regulatory pathway and activation of
ERK/caldesmon and actin polymerization, but inhibits a i-adrenoceptor-mediated
contractions in pregnant uterine artery through down-regulation of the thick filament
pathway and decreased myosin light chain phosphorylation. Taken together, the results
suggest a transition of subcellular localization of PKCp and 8 from thin filaments to thick
filaments in the uterine arteries during pregnancy. Given the finding that steroid
hormones induced modulation of cytosolic and membrane-bound regulatory proteins
including PKC, and regulate their function (Simoncini et ah, 2000; Kelly and Levin,
2001; Simoncini et ah, 2002; Tostes et. al, 2003; Orshal and Khalil, 2004), steroid
hormones might play an important role in this thin-thick filament transition and the
regulation of a i-adrenoceptor signaling pathways in the uterine arteries.
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Conclusion and Implications
In conclusion, the present research project has demonstrated the opposite effects of
PKC on ai-adrenoceptor-induced contractions in nonpregnant and pregnant uterine
arteries. Activation of PKC potentiates ai-adrenoceptor-induced contractions in
nonpregnant uterine arteries by increasing Ca sensitivity through the thin filament
regulation pathway, but inhibits the contractions in pregnant uterine arteries by
suppressing the Ca -dependent thick filament regulation pathway. The findings of upregulation of the PKC isozymes that inhibit intracellular Ca mobilization, downregulation of the PKC isozymes that increase Ca sensitivity, and a transition of
subcellular localization of PKCp and c from thin filaments to thick filaments in the
uterine arteries during pregnancy provide insights into the adaptation of uterine artery
contractile mechanisms in pregnancy. Steroid hormones might play an important role in
this contractile adaptation to pregnancy, since estrogen has been suggested to decrease
vascular tone through modulating Ca homeostasis in vascular smooth muscle cell
(Duckies SP, 1996; Orshal JM, 2004; Suzuki T, 2003). In addition, steroid hormones
induced modulation of cytosolic and membrane-bound regulatory proteins including
PKC, and regulate their function (Simoncini et al., 2000; Kelly and Levin, 2001;
Simoncini et al., 2002; Tostes et. al, 2003; Orshal and Khalil, 2004). From the
physiological perspective, the uterine circulation during pregnancy functions as a lowresistance shunt to accommodate the large increase of uteroplacental blood flow, required
for normal fetal development. In addition to growth and remodeling of vessels, the
decreased uterine artery resistance is accomplished by increased endothelial nitric oxide
release, decreased myogenic response, and a reversible sympathetic denervation of the
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uterine artery. However, at the same time, uterine artery increases acute contractile
response to nonsynaptic a i-adrenergic stimulation throughout gestation (Annibale DJ,
1989 & 1990; D’Angelo G, 1993 & 1994; Osol G, 1993), and retains its ability to
phasically contract to shunt blood away from the uterus to other vascular beds during
times of acute maternal stress to facilitate maternal survival. Nevertheless, when stress is
prolonged, myogenic tone is continuously increased with activated PKC. This PKC
activation is suggested in the present studies to reduce ai-adrenoceptor-mediated
contractions in pregnant uterine artery. The finding of increased PKC-mediated inhibtion
on ai-adrenoceptor-mediated contractions reveals another important mechanism in
maintaining the low uterine vascular tone during chronic stress, such as pregnancy, to
facilitate fetal survival and normal development. The present studies enhance our basic
understanding of uterine vasculature adaptation to pregnancy, help provide a mechanistic
basis for this functional adaptation, and thereby improve our understanding of problems
associated with the maladaptation and abnormal pregnancy and permit us to address them in
a more meaningful way.
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